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It is now established that adipose tissue macrophages, which accumulate in obese 
individuals and rodents, play a key role in the generation of a low-grade, chronic 
inflammation, as well as the development of steatosis and insulin resistance, when 
faced with chronic overnutrition.  The hypothesis of this dissertation is that other cells of 
the immune system and inflammatory responses within other insulin sensitive organs 
are also involved in the metabolic regulation of nutrient utilization.  Specifically, we 
tested the responses of dendritic cells (DC), Kupffer cells (KC, the resident 
macrophages of the liver) and Natural Killer T (NKT) cells in the liver, as well as in 
adipose tissue. 
To address this hypothesis, we developed two model systems to artificially alter 
the immune system while monitoring changes within the liver and/or adipose tissue.  
First, we established an in vitro co-culture model of the liver with mouse hepatocytes 
and KC to study interactions between the two cell types.  Second, we established an 
adoptive transfer protocol to exogenously increase the numbers of macrophages and 
various types of DC in mice consuming a high fat diet.  Finally, we utilized the CD1d-/- 
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mouse line to clarify an important controversy regarding the involvement of NKT cells in 
the metabolic disturbances of obesity. 
We found that KC decrease hepatocyte palmitate oxidation and identified 
prostaglandin E2 (PGE2) as a potential mediator of this effect.  Furthermore, the liver 
and adipose tissue of mice receiving weekly injections of immature bone marrow-
derived DC are skewed towards a predominantly TH2, or anti-inflammatory, phenotype.  
Additionally, these mice accumulate less fat and are partially protected against diet-
induced insulin resistance.  Also, we illustrate that removal of NKT cells does not alter 
insulin resistance or steatosis when consuming a high fat diet (HFD). 
In conclusion, we have demonstrated that responses of immune cells within the 
liver alter lipid metabolism and can induce changes consistent with the development of 
steatosis.  Additionally, DC play an integral role in the determination of body 
composition and insulin sensitivity when challenged with a HFD.  And finally, NKT cells 
may not be involved in the development of the metabolic disturbances of obesity. 
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1.0  CHAPTER 1 – INTRODUCTION 
1.1 OBESITY, DYSLIPIDEMIA, INSULIN RESISTANCE AND TYPE II DIABETES 
MELLITUS 
Obesity and type 2 diabetes mellitus (T2DM) are two diseases that are growing in 
prevalence to epidemic proportions.  The World Health Organization recently reported 
that over 1.5 billion adults worldwide are overweight, and of those, 500 million are 
obese [1].  In the United States alone, the Center for Disease Control reports that over 
one-third of the adult population is obese [2].  Insulin resistance (IR) and dyslipidemia 
are hallmarks of obesity that predispose those persons towards the development of 
T2DM and non-alcoholic fatty liver disease (NAFLD).  Notably, T2DM is the leading 
cause of new blindness among adults age 20-74, the leading cause of kidney failure 
and the cause of more than 60% of non-traumatic lower-limb amputations.  Also, 
patients with T2DM are at increased risk for heart disease, hypertension, and stroke [3].  
Although there has been much progress, the physiological, biochemical and molecular 
mechanisms linking obesity, dyslipidemia, IR, and T2DM remain ill-defined.  
Understanding these mechanisms is critical to the development of new treatments and 
to decreasing the morbidity and mortality associated with these diseases.  In this 
dissertation, I will present work which further implicates an involvement of the innate 
 2 
immune system in the pathogenesis of the metabolic disturbances of obesity and 
describe a novel mechanism for these changes. 
1.2 INFLAMMATION AND DYSREGULATED METABOLISM IN OBESITY 
Many potential mechanisms have been suggested as a link between obesity and insulin 
resistance.  Inflammation is one of the earliest reported of such mechanisms.  Studies 
as far back as the 1800s by Professor Wilhelm Ebstein demonstrated an association 
between inflammation and obesity/T2DM when he showed that high dose sodium 
salicylate (a related compound to the anti-inflammatory medication acetylsalicylic acid, 
a.k.a. aspirin) dramatically reduces glycosuria in diabetic patients [4].  Indeed, 
epidemiologic reports of increased inflammation in patients with obesity and T2DM had 
been made for almost 50 years, when it was discovered that the serum of diabetics and 
obese patients exhibit lower fibrinolytic activity, a process closely linked with 
inflammation that protects against atherosclerosis [5-7].  Further correlative studies 
reported that obese and T2DM individuals have increased circulating levels of pro-
inflammatory cytokines.  Hotamisligil and colleagues demonstrated that tumor necrosis 
factor α (TNFα) is elevated in the plasma and adipose tissue of obese patients.  They 
also noted that weight loss significantly improves insulin resistance, as well as lowers 
the concentrations of TNFα in these subjects [8,9].  These studies were followed by 
those of Straczkowski et al., which showed that Interleukin (IL)-8 concentrations in the 
bloodstream correlates with fat mass and waist-to-hip ratio, both metrics of obesity [10].  
Interestingly, monocyte chemoattractant protein 1 (MCP-1), a chemokine known to 
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recruit monocytes to areas of inflammation, is also elevated in the adipose tissue of 
obese mice [11].  Additionally, the studies of Creely et al. [12] provided some insight as 
to how this inflammation arises.  They described that circulating endotoxin (bacterial 
lipopolysaccharide, LPS), which is elevated in the plasma of obese and T2DM 
individuals, causes cultured human adipocytes to release the pro-inflammatory 
cytokines TNFα and IL-6.  Further, they noted that treatment of diabetic patients with 
rosiglitazone, an insulin sensitizing thiazolidinedione, decreases both fasting 
hyperinsulinemia and endotoxemia [12].  While these studies all indicate an association 
between elevated inflammation and metabolic dysfunction in diabetic and obese 
subjects, there have since been a number of reports showing a causative relationship 
between the inflammatory responses and metabolism. 
Work by Cani et al. [13,14] expanded on the findings of Creely et al. [12] to show 
that exogenous and endogenous LPS from the gram-negative bacteria in the gut 
contribute to endotoxemia in the presence of a high fat diet (HFD).  Thus, a continuous 
infusion of LPS in mice induces obesity and diabetes [13].  Furthermore, they showed 
that a HFD alters the gut microbiota [13], that by experimentally altering the constituents 
of the bacterial population of the gut, they could reduce endotoxemia and protect 
against the development of diabetes [14] and that HFD increases the permeabilization 
of the gut to LPS [14].   
While the groundwork for the concept of immune modulation of metabolism (i.e. 
cells of the immune system altering nutrient utilization), may have been established by 
the work of Ebstein [4], the field truly had its inception in the mid-1990s, when 
Hotamisligil and colleagues demonstrated that an infusion of a neutralizing antibody 
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against the pro-inflammatory cytokine TNFα, protects Zucker fatty rats from insulin 
resistance [15].  Furthermore, mice lacking the TNFα gene gain similar amounts of 
weight as wild-type animals, but are protected against insulin resistance when placed 
on a HFD [16].  Additionally, bone marrow transplant of wild type bone marrows into 
TNFα knock-out mice, re-instates the insulin resistance caused by high fat feeding [17].  
The work of Shoelson, Shulman and colleagues expanded on Ebstein’s initial findings to 
show that salicylates substantially improve insulin sensitivity and glucose tolerance, and 
decrease fasting serum triglyceride and free fatty acid levels in genetic and diet-induced 
models of obesity [18], as well as improving insulin sensitivity in lipid-infused rats [19] 
and diabetic humans [20].  They also implicated the pro-inflammatory NF-κB pathway in 
these effects, when they demonstrated that enhancing the action of NF-κB or IKKβ 
promotes insulin resistance [21], and disrupting IKKβ activity protects against genetic 
and diet-induced models of insulin resistance [18,19,21].  Notably, activation of NF-κB 
results in the production of the pro-inflammatory cytokines TNFα, IL-1, and IL-6 [22,23].  
Salicylates, contrary to most other NSAIDs, which primarily target the cyclooxygenase 
(COX) proteins COX-1 and COX-2, also inhibit the action of IKKβ and subsequently 
decrease TNFα production [24].  Arkan and colleagues provided further evidence that 
inflammation and immune cells can drive metabolic changes, by reporting that a 
myeloid-specific knock out of the IKKβ gene imparts protection from diet-induced insulin 
resistance [25]. 
Over the past decade, a number of reports have linked increased inflammation 
with obesity, IR, and dyslipidemia [26-33].  There is now believed to be a causal 
relationship between inflammation and the metabolic disturbances seen in obesity.  
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While the work of Cani and Creely implicate endotoxin as an activating molecule, we 
have been interested in ascribing a role to another molecule known to be highly 
elevated in the bloodstreams of obese patients: fatty acids.   
1.3 FATTY ACID EFFECTS ON THE TISSUES 
1.3.1 Physiologic handling and signaling of lipids 
When our body ingests a lipid-rich meal, gastric and pancreatic lipases start the 
digestion process to break dietary fats, usually in the form of triglycerides (TG), into its 
component parts of fatty acids and glycerol.  Once they reach the small intestine, bile 
salts, produced in the liver and stored in the gall bladder, emulsify the fats to increase 
the surface area to volume ratio, making the lipolytic process more efficient.  The fatty 
acids and glycerol are transported into the enterocytes of the small intestine, where they 
are re-esterified into TG, before being packaged into chylomicrons and dumped into the 
lymphatics for delivery to the tissues (Figure 1).  We know from multiple reports that the 
concentrations of plasma free fatty acids (FFA) are elevated in obese and T2DM 
patients [34-36] and, in addition to LPS, we are beginning to understand that these high 
levels of lipids in the bloodstream may contribute to sequelae of these diseases.   
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Figure 1 - Physiologic handling of lipids1 
 
Interestingly, Toll-like receptor 4 (TLR4), the receptor for LPS, has also been 
implicated as the receptor for fatty acids [37-39].  Toll-like receptors are a family of 
receptors known for their involvement in innate immune responses, recognizing 
conserved, antigenic molecular patterns, such as those present in bacterial LPS and 
CpG, viral DNA and fungal zymosan [40-42].  TLR4 first signals through the adaptor 
protein MyD88 and then causes activation of NF-κB, which includes translocation to the 
nucleus, binding to DNA and subsequently altering gene transcription.  Lee and 
colleagues demonstrated that saturated fatty acids, but not unsaturated fatty acids, 
activate NF-κB and induce gene expression of COX-1 in macrophages, a process 
requiring the presence of functional TLR4, MyD88, IκBα, and the PI-3K/Akt signaling 
                                                
1 Adapted with permission from Fauci AS, Kasper DL, Braunwald E, Hausler SL, Longo DL, Jameson JL, 
Loscalzo J: Harrison’s Principles of Internal Medicine, 17th Edition, http://www.accessmedicine.com.  
Copyright © The McGraw-Hill Companies, Inc.  All rights reserved.  In no event shall McGraw-Hill have 
any liability to any party for special, incidental, tort, or consequential damages arising out of or in 
connection with the McGraw-Hill material.  
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pathway [37,43].  Furthermore, lipid infusion causes NF-κB to bind to DNA in wild type 
mice, but not in TLR4 knock out adipose tissue, and TLR4 deficiency protects against 
skeletal muscle insulin resistance [38].  Additionally, mice lacking TLR4 are protected 
against insulin resistance and steatosis when placed on a HFD ([39] and O’Doherty, 
unpublished observations), although they are not protected against the weight gain and 
insulin resistance caused by a diet with elevated trans fat [44].  Interestingly, even 
though saturated FFA and LPS both activate TLR4, the effects of these two molecules 
can be quite different, as I will describe in more detail in Chapter 2.   
Fatty acids have also been shown to signal through AMP-activated protein 
kinase (AMPK).  AMPK is a nutrient sensor within the cell that monitors the energy 
status (by detecting the AMP:ATP ratio) and modulates cellular processes to adapt to 
the current environment [45].  AMPK is also a potent activator of fatty acid oxidation 
through its inhibition of the lipogenic enzyme acetyl-CoA carboxylase (ACC) [45,46].  
Both the saturated fatty acid palmitate and the poly-unsaturated fatty acid linoleate 
activate AMPK in L6 myotubes, and a dominant-negative form of AMPK completely 
blocks the fatty acid induced increases in β-oxidation [47].   
1.3.2 Effects of fatty acids on insulin response 
Studies in rodents [48,49] and humans [50-52] have demonstrated that an acute lipid 
infusion reduces insulin-stimulated glucose uptake.  Additionally, chronic exposure to 
elevated fatty acids causes the accumulation of lipids in non-adipose tissues, which 
interferes with normal functioning, including the suppression of insulin secretion from 
pancreatic β-cells [53], a concept referred to as lipotoxicity.  These changes are 
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apparently caused by activation of protein kinase Cθ (PKCθ) [49,54], which then 
phosphorylates serine/threonine residues on the insulin receptor, dampening the 
response to insulin.  Chronic elevations of fatty acids also impair insulin sensitivity in 
rodents, but less evidence exists in larger animals and humans [55].   
Together with the liver and skeletal muscle, adipose tissue is one of the three 
major insulin responsive organs in the body.  White adipose tissue, once thought to be 
simply a repository for the fat stores of the body, is now recognized as a significant 
player in total body fat metabolism and nutrient homeostasis via the production of 
adipokines, cytokines, and chemokines [56]. In response to insulin, adipose tissue 
stores lipid in the form of triglyceride (TG), thus decreasing the levels of circulating 
plasma FFA postprandially, and maintaining the energy stores for when they are 
required during periods of fasting.  Insulin is a potent inhibitor of lipolysis, such that in 
states of insulin resistance, lipolysis may not be suppressed, leading to a vicious cycle 
of FFA causing insulin resistance, and insulin resistance resulting in the release of more 
FFA into the bloodstreams of obese and T2DM patients.  Along these lines, elevated 
FFA decrease insulin responsiveness and increase TNFα production in cultured 3T3L1 
adipocytes [57].  Treatment of rat adipocytes with high concentrations of FFA also 
decreases insulin-stimulated glucose transport [58].   
Skeletal muscle accounts for approximately 90% of the insulin-stimulated 
glucose removal after a meal [59].  In binding to its receptor, insulin causes a tyrosine 
kinase cascade, ultimately activating PI3K and Akt, resulting in the translocation of 
GLUT4 glucose transporters to the cell surface [60].  Accordingly, elevations in fatty 
acids have also been implicated in skeletal muscle insulin resistance.  In response to an 
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acute challenge with FFA, myocytes exhibit decreased rates of insulin-stimulated 
glucose uptake, decreased phosphorylation of key signaling proteins downstream of the 
insulin receptor [52] and decreased insulin-stimulated glycogen synthesis [61].  Notably, 
activation of AMPK reverses this blockage [61].  Additionally, lipid infusions abolish IRS-
1-associated PI-3-kinase activity in both humans [62] and mice [63].  Moreover, mice 
lacking TLR4 are protected against this decrease [63]. 
The liver is a critical modulator of systemic lipid and carbohydrate metabolism 
[64].  It is a primary target of insulin action, is positioned anatomically as the first post-
absorptive organ to process most nutrients and gut endotoxin and processes most of 
the FFA released from the adipose tissue in the fasted state.  In the obese state, the 
liver becomes engorged with fat [i.e. non-alcoholic fatty liver disease (NAFLD)].  
NAFLD, now considered the hepatic manifestation of the metabolic syndrome [65], and 
the profound effects of hepatic insulin resistance on systemic metabolism, exemplify the 
importance of liver dysfunction in obesity.  In healthy, lean subjects, decreases in 
plasma FFA concentrations decrease gluconeogenesis, but also increase 
glycogenolysis, such that the endogenous glucose production from the liver remains 
constant.  Accordingly, increases in plasma FFA increase gluconeogenesis and 
decrease glycogenolysis at equal rates [50,66-68], however the mechanism of these 
changes are currently unknown.  In states of insulin resistance, elevated serum FFA 
cause an increase in gluconeogenesis, however the liver is unable to coordinately 
modulate glycogenolysis, thus leading to hyperglycemia [69,70].  Importantly, the liver 
has its own extensive, resident immune system, which includes macrophages (Kupffer 
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cells), T cells, Natural Killer T (NKT) cells, Natural Killer (NK) cells and dendritic cells 
[71]. 
The interplay between inflammation and insulin resistance is now widely 
accepted.  Particularly in the past decade, significant effort has been devoted to defining 
the mechanisms and cell types involved [30,32].   
1.4 B AND T CELLS IN OBESITY 
B and T cells are the major effector cells of the adaptive immune system.  B cells 
classically serve as the producers of antibodies and the generation of humoral 
immunity.  T cells act to destroy host cells that have become infected with pathogens 
(CD8+ cytotoxic T cells, TC) or act to assist other cells in enhancing their function 
through the production of cytokines (CD4+ helper T cells, TH) [72].  Of particular interest 
to the work described here, helper T cells have two predominant subsets, TH1 and TH2, 
as well as a newly recognized third subset, TH17, which are all defined by the cytokines 
they produce.  TH1 cells secrete their quintessential cytokine, IFNγ [73], which is 
classically pro-inflammatory, [74] and drive macrophages down the “classical activation” 
or M1 pathway [75].  On the other hand, TH2 cells secrete their signature cytokines IL-4, 
IL-5, IL-10 and IL-13 [73], are classically anti-inflammatory [74], and drive M2 or 
“alternative activation” of macrophages [75].  TH17 cells produce IL-17 and IL-22 and 
are most abundant at mucosal surfaces such as the intestinal lamina propria [76].  
These cells have recently been ascribed an important role in mediating anti-
inflammatory responses and may play a role in the metabolic imbalance of obesity [77].  
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Furthermore, another type of T cell, regulatory T cells (Treg), have also recently been 
implicated in both rodent models and human obesity [78].  Nishimura and colleagues 
[79] demonstrated that CD8+ T cells play a role in the development of the metabolic 
disturbances of obesity when they showed mice depleted of CD8+ are protected against 
insulin resistance and adipose tissue inflammation when placed on a HFD.   
In addition to producing antibodies, activated B cells also have some phagocytic 
and antigen-presenting capabilities.  Thus, they can modulate T cell responses to 
specific antigens [72].  B cells have recently been shown to promote insulin resistance 
when mice are placed on a HFD through both the production of pathogenic antibodies 
as well as their interactions with T cells [80].   
While recognizing the importance of B and T cells to the pathogenesis of obesity 
and insulin resistance, this work is primarily aimed at determining the roles that three 
different immune cell types, macrophages, dendritic cells and NKT cells, play in the 
development of the metabolic disturbances found in obesity.  Below, I describe the role 
of each of these cell types as is accepted in the field at this point in time. 
1.5 MACROPHAGES IN OBESITY 
Macrophages are a heterogeneous population of myeloid-derived mononuclear cells 
that are a critical component of the innate immune response.  They are the “garbage 
collectors” of the immune system: they phagocytose pathogens, degrade them, then 
present the antigens complexed with MHC molecules to activate and differentiate T 
cells with the complementary receptor [72].  A classic pro-inflammatory activator of 
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macrophages is the LPS component of endotoxin, acting through TLR4.  More recently, 
saturated FFA, which are abundant in the plasma of obese patients, have been reported 
to act on macrophages via a similar mechanism [37,43].  Macrophages are the best 
studied of the immune cells in terms of their responses in metabolism: a number of 
seminal studies [81-84] have established that adipose tissue macrophages (ATM) are a 
contributing factor to the insulin resistance and metabolic deregulation seen in obese 
individuals. 
In 2003, two papers described that, in both humans and mouse models of 
obesity, macrophages infiltrate into white adipose tissue (WAT) and the degree of ATM 
accumulation correlates with adiposity and measures of IR [84,85].  Furthermore, these 
macrophages are key contributors to the increased inflammatory status of obese 
individuals.  Of note, mice with a reduced capacity to recruit macrophages (MCP-1 or 
CCR2 null) demonstrate reduced inflammation in fat, protection from HFD-induced IR 
and reduced ATM content [83,86], while stimulation of macrophage recruitment induces 
IR [87].  Notably, ATMs in obese animals tend to be M1 or “classically activated”, which 
produce pro-inflammatory cytokines, such as TNFα, IL-6, and IL-12 and reactive oxygen 
species via iNOS.  They also promote TH1 polarization of the T cells they activate.  The 
macrophages in lean WAT tend to be M2 or “alternatively activated”, which produce 
anti-inflammatory cytokines, such as IL-10 and IL-1R decoy, and promote TH2 
polarization.  Subsequent work further characterized the ATMs, the inflammatory 
pathways involved and the role of macrophages in the development of IR, dyslipidemia 
and obesity [25,82-85,87,88]. Together, these seminal studies clearly demonstrate a 
role for ATMs in the pathogenesis of IR and dyslipidemia in obesity.  Macrophages, 
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however, are also particularly enriched in tissues, such as the liver, that are frequently 
exposed to exogenous and endogenous antigens and toxins.  The potential role of liver 
macrophages [Kupffer cells (KC)] in the development of these metabolic abnormalities 
is largely unknown, although recent studies have implicated such a role [89,90].   
Our lab has shown that rats depleted of KC with gadolinium chloride injection are 
resistant to the development of insulin resistance and steatosis [91].  In addition, an in 
vitro co-culture system in rats showed that incubation of activated KC with hepatocytes 
lowers palmitate oxidation and IRS-1 associated PI3K activity, and increases palmitate 
esterification and TG accumulation [91].  Furthermore, similar to the numbers of 
macrophages in the adipose tissue, the numbers of KC increased when mice were 
placed on a long-term HFD (Stefanovic-Racic et al., submitted).   
As I will describe in Chapter 2 and Appendix A, I have developed an in vitro 
system with mice to study interactions between hepatocytes and KC.  Similar to the rat 
system, we show that mouse KC cause a decrease in hepatocyte palmitate oxidation 
(Appendix A).  Additionally, we have identified the eicosanoid prostaglandin E2 (PGE2) 
as a potential mediator of this response (Chapter 2).  Thus, KC play an integral part in 
the development of NALFD in obese subjects, at least in part, by impairing the capacity 
of hepatocytes to break down lipid.   
1.6 DENDRITIC CELLS IN OBESITY 
Dendritic cells (DC) are bone marrow-derived, professional antigen presenting cells 
(APC) that play a key role in the development of innate and adaptive immune 
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responses, as well as in mediating tolerance to self antigens [92-94].  Dendritic cells are 
more efficient APCs than B cells or macrophages at activating naïve T cells, because B 
cells and macrophages must be activated before they can present antigen and they do 
so with a limited number of MHC molecules.  Also, immature DC are poised to capture 
antigen, while mature DC constitutively express high levels of MHC and the co-
stimulatory molecules required to activate T cells [72,92].  Similar to macrophages, DC 
can polarize an immune response in a TH1 or TH2 fashion, and the bacterial endotoxin, 
LPS, is the classical stimulatory molecule that allows DC to polarize T cells towards a 
TH1 phenotype.  LPS causes DC maturation and activation via TLR4 [95], and saturated 
FAs have also been shown to activate DC through TLR4 [95].   
Much less is known at this point about the responses of DC in obesity and T2DM.  
Macia and colleagues [96] described an elevation of DC numbers in the auricular 
epidermis of leptin deficient ob/ob mice.  Furthermore, bone marrow-derived DC 
(BMDC) from ob/ob mice do not activate T cells as readily as those from wild type 
animals [96].  Recently, two studies [97,98] described a novel population of monocytes 
that increase in obesity and, in addition to expressing the classical macrophage markers 
F4/80 and CD11b, express the CD11c marker (“triple positive cells”).  This is an 
important observation since CD11c is a classical DC marker, suggesting that DC may 
be increased in obesity.  Recently, Patsouris and colleagues reported on a transgenic 
mouse model that was depleted of all CD11c+ cells [99].  The authors demonstrate that 
depletion of triple positive cells results in improved insulin sensitivity.  Notably, only half 
of all the CD11c+ cells that were depleted are triple positive.  Thus, the majority of the 
cells that are still CD11c+, but are not triple positive cells, are likely DC and could also 
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explain the observed improvement in insulin sensitivity.  Furthermore, Nguyen and 
colleagues [100] demonstrated that triple positive BMDC produce higher levels of pro-
inflammatory cytokines than bone marrow-derived macrophages (BMDM), which only 
express F4/80 and CD11b, at baseline and in response to FFA.  Interestingly, the 
response to FFA was not seen with TLR2/TLR4 double knock out BMDC.  This 
discrepancy has major implications for the timely generation of therapeutics, since work 
has already been devoted to investigating the use of DCs for vaccine and oncological 
purposes. 
Our lab has found that mice placed on a long-term HFD have increased numbers 
of DC in both the WAT and liver, and that the changes in the liver are an early and 
reversible change, after only 3 weeks on the HFD (Stefanovic-Racic, et al., submitted). 
Furthermore, our collaborators have described that non-obese diabetic (NOD) mice, a 
mouse model of type I diabetes mellitus, injected with BMDC are protected against the 
development of diabetes [101]. 
As addressed in Chapter 3, we sought to expand on these findings to determine 
if injection of BMDC could protect against the development of T2DM.  We generated 
immature BMDC (iDC), LPS-activated BMDC (LPS-DC), and BMDM and found that 
iDC, but not LPS-DC or BMDM, decreased weight gain and improved glucose 
tolerance.  Furthermore, injection of iDC caused immune cell infiltration into liver and 
WAT, and these cells were skewed towards a TH2 phenotype. 
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1.7 NKT CELLS IN OBESITY 
Natural killer T (NKT) cells are a sub-population of lymphocytes that are proposed to 
serve as a link between the adaptive and innate immune systems [102-104] and have 
receptor expression characteristics of both NK cells (they are NK1.1+) and T cells [they 
express a T cell receptor (TCR)].  Notably, the NKT TCR, rather then being activated by 
peptide antigens, is activated by glycolipid antigens through the MHC class I-like 
molecule, CD1d [102-104], while an alternative activation pathway is dependent on 
cytokine signaling from activated dendritic cells [103].  Irrespective of the method, 
activation of NKT cells results in rapid cytokine production (within hours), which may be 
of mixed, TH1 or TH2, dominance depending on the microenvironment to which the NKT 
cells are exposed [104].   
Given the abundance of circulating FFA in obese patients, and the fact that NKT 
cells recognize glycolipid antigens, NKT cells are a logical potential mediator for the 
effects of lipid rich diets on metabolism.  However, there is currently controversy in the 
field regarding the involvement of NKT cells in the development of the metabolic 
disturbances of obesity.  Studies have indicated that NKT cells are more TH1 polarized 
in obesity [105], and administration of the NKT activator α-galactosylceramide 
exacerbates glucose intolerance and adipose tissue inflammation [106], suggesting a 
pathogenic role of NKT cells in obesity.  Conversely, other studies indicate that NKT cell 
numbers are decreased in the liver (the predominant site of NKT cells) [107-109], and 
adoptive transfer of NKT cells improves glucose tolerance and steatosis in ob/ob mice 
[110], which suggests a protective role for NKT cells in the development of the 
metabolic abnormalities of obesity.  Furthermore, one group reported that mice lacking 
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NKT cells are protected from HFD-induced adipose tissue inflammation and glucose 
intolerance, although importantly, the mouse model used in this study also lacks CD8+ T 
cells [106]. 
As we detail in Chapter 4, mice that specifically lack NKT cells are not protected 
against weight gain, adiposity, insulin resistance, or steatosis when placed on a HFD 
[107].  Thus, research efforts designed to ameliorate the sequelae of obesity should 
concentrate on cell types other than NKT cells. 
1.8 STATEMENT OF THE PROBLEM 
When I first undertook these projects, the field contained a preponderance of research 
describing a pathogenic role for macrophages in adipose tissue inflammation and the 
subsequent metabolic changes observed in obesity.  We believe that other insulin 
sensitive organs, such as the liver, may also play a role in the generation of the 
metabolic disturbances of obesity.  Furthermore, other cells of the immune system may 
be involved in the generation of the inflammation and metabolic abnormalities present in 
overnutrition.  Our overarching hypothesis was that DC, KC and NKT cells are also 
integral in the metabolic changes of obesity.  Specifically, throughout the work 
described, we aimed to manipulate these immune cell populations individually and 
measure known parameters of metabolism, in vivo and in vitro, to determine any 
metabolic changes in response to each.   
The goal of this work was not necessarily to discover a way to prevent obesity 
and T2DM, but rather to discover mechanisms by which the sequelae of these diseases 
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arise, such that even in the face of these diseases, we can develop new treatments to 
reduce the associated morbidity and mortality.  The research detailed below is novel in 
that we look not only at responses in adipose tissue, but also in other insulin sensitive 
organs such as the liver.  Additionally, we detail a direct effect of dendritic cells in the 
development of the metabolic disturbances of obesity.   
In our proposed model of the immune modulation of metabolism (Figure 2), FFA, 
which are elevated in the bloodstream of obese and T2DM patients, bind to TLR4 on 
the surface of adipocytes, hepatocytes and the resident immune cells of the liver and 
adipose tissues, such as KC.  This activates a signaling cascade that ultimately leads to 
the expression of various chemokines in these cells.  At the same time, DC in the 
tissues phagocytose a currently unknown antigen, become activated, travel to the lymph 
nodes, and present the antigen, complexed with an MHCII molecule, to T cells with the 
cognate T cell receptor (TCR).  This MHCII-antigen:TCR interaction initiates the process 
of T cell activation, however, these T cells are not yet committed to a specific 
polarization.  The production of chemokines in the tissues recruits DC, macrophages 
and T cells, where the presence of activated DC and a pro-inflammatory cytokine milieu 
influences the incoming T cells to assume a TH1 polarization, which further adds to the 
pro-inflammatory status of the tissues.  Recruited and resident macrophages also 
produce PGE2, which acts directly on the hepatocyte to alter β-oxidation.  Furthermore, 
the pro-inflammatory cytokines, produced by the DC, macrophages and T cells, act 
directly on the tissues to decrease insulin responsiveness. 
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Figure 2 - Proposed model of immune modulation of metabolism 
Elevated circulating levels of FFA, as seen in obese patients, activate TLR4 signaling in the 
parenchymal cells of the liver and adipose tissue, as well as resident immune cells, such as KC.  
This signaling cascade ultimately leads to the production of MCP-1, which recruits cells of the 
monocyte/macrophage and DC lineages to the tissues.  The cytokine milieu produced by these 
cells along with T cells, which are recruited and activated upon recognition of a currently unknown 
antigen, skew the tissues towards a TH1 phenotype.  The pro-inflammatory factors produced 
reduce insulin sensitivity in these tissues resulting in decreased lipid oxidation in hepatocytes and 
increased lipolysis in adipoctyes. Abbreviations used: FFA, free fatty acids; TLR4, toll-like 
receptor 4; KC, Kupffer cells; MCP-1, monocyte chemoattractant protein-1; DCs, dendritic cells; 
PGE2, prostaglandin E2; TNFα, tumor necrosis factor α; IL, interleukin; IFNγ, interferon γ; Ins 
Sens, insulin sensitivity; FAOx, fatty acid oxidation. 
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2.0  CHAPTER 2 – PROSTAGLANDIN E2, PRODUCED BY PALMITATE-
ACTIVATED KUPFFER CELLS, DECREASES HEPATOCYTE LIPID OXIDATION 
2.1 ABSTRACT 
Kupffer cells (KC), the resident macrophages of the liver, have recently been implicated 
in the generation of the inflammation and subsequent metabolic changes observed 
coincident with chronic diseases such as obesity and type II diabetes mellitus.  In this 
study, we describe a mechanism of KC-mediated alterations in hepatocyte metabolism 
involving the inflammatory lipid mediator prostaglandin E2 (PGE2).  We hypothesized 
that PGE2, produced by Kupffer cells, will decrease hepatocyte lipid oxidation leading to 
the development of steatosis and insulin resistance.   
To address this question, primary mouse hepatocytes and Kupffer cells were 
isolated and co-cultured using a trans-well system.  Lipid metabolism was assessed in 
co-cultures and hepatocyte monocultures in response to PGE2 treatment.  Additionally, 
mice lacking the microsomal PGE2 synthase-2 gene (Ptges2 KO) were exposed to a 
high fat diet, and weight gain, food intake, body composition, metabolic rate and insulin 
sensitivity were measured. 
KC inhibited palmitate oxidation in cultured mouse hepatocytes.  Treatment of 
co-cultures with indomethacin completely abrogated this decrease in oxidation.  PGE2 is 
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produced by palmitate-activated KC and exogenous treatment of hepatocytes with 
increasing doses of PGE2 decreased palmitate oxidation in the absence of KC.  KC also 
inhibited palmitate esterification, although PGE2 does not replicate this effect.  Ptges2 
KO mice gained more fat mass than their age-matched wild type controls, without stark 
changes in insulin sensitivity. 
These data implicate PGE2 in the metabolic disturbances of obesity.  Specifically, 
PGE2 may be necessary for the KC depression of hepatocyte palmitate oxidation, which 
is consistent with the development of steatosis and insulin resistance in conditions of 
overnutrition, such as obesity and high fat feeding. 
2.2 INTRODUCTION 
Obesity and type II diabetes mellitus coincide with a state of chronic, low-grade 
inflammation, which has been implicated in the pathogenesis of insulin resistance and 
dyslipidemia.  Mounting evidence points to a role of adipose tissue macrophages in the 
development of this inflammatory state and the metabolic disturbances of obesity [81-
86].  Notably, macrophages are increased in number and activity in both human obesity 
[81,82] and rodent models of diet induced obesity [84,85].  Interest persists, however, in 
exploring the effects of the immune system on other insulin sensitive organs.  Indeed, 
the resident macrophages of the liver, Kupffer cells (KC), have recently been implicated 
in the generation of steatosis and insulin resistance when mice consume a high fat diet 
(HFD) [89,90].  We have found that KC are increased in the livers of mice that have 
been placed on a HFD for 26 weeks, by which time stark steatosis has set in 
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(Stefanovic-Racic, et al., submitted).  Furthermore, we have shown, in rats, that 
depletion of KC protects against the development of steatosis in the setting of a HFD 
[91].  The mechanisms by which KC may influence the development of steatosis remain 
to be elucidated.  KC produce a number of inflammatory mediators, some of which have 
been implicated in altering metabolism and insulin sensitivity.  Chief among these have 
been cytokines, such as TNFα, IL-6 and IL-8 [10,15,111].  Macrophages, however, also 
produce lipid-derived molecules that serve as potent inflammatory signals.  One class of 
such molecules is the prostaglandins, one member of which, prostaglandin E2 (PGE2), 
has previously been implicated in the regulation of hepatic metabolism. 
 PGE2 is a lipid mediator derived from arachidonic acid (AA).  It has been 
classically described as a pro-inflammatory molecule, is produced acutely, in large 
amounts, in inflammatory states and causes the cardinal signs of inflammation: rubor 
(redness – erythema), tumor (swelling – edema), calor (heat – fever) and dolor (pain) 
[112].  AA is first oxidized to PGH2 by the cyclooxygenase enzymes (COX-1 and COX-
2).  PGH2 is then further oxidized by one of the three terminal PGE2 synthases (cPGES, 
mPGES-1 or mPGES-2) to generate PGE2 [113].  PGE2 signals primarily through four 
E-prostanoid receptor subtypes, designated EP1-EP4 [114].  These receptors are 
coupled to different G-proteins (EP1 to Gq, EP3 to Gi, and EP2 and EP4 to Gs), which 
likely account for the wide variety of effects attributed to PGE2, often within the same 
tissue [115,116].   
Importantly, PGE2 has also been shown to have various metabolic functions.  
Studies have implicated PGE2 in glucose metabolism, demonstrating both stimulation of 
glycogenolysis [117-119] and inhibition of glucagon-stimulated glycogenolysis [120-123] 
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depending on the receptors engaged and signaling pathways involved [119].  
Furthermore, PGE2 causes an increase in glycogen synthesis [124] and 
gluconeogenesis [118].  PGE2 has also been implicated in lipid metabolism, as it inhibits 
VLDL secretion [125] and glucagon-stimulated β-oxidation [126].  Also, KC-derived 
PGE2 inhibits lipid synthesis in cultured rat hepatocytes [127].  However, any direct 
effects of PGE2 on hepatocyte lipid oxidation have yet to be determined.  The current 
study was undertaken to address this issue.  To accomplish this goal, we developed a 
co-culture system to measure lipid oxidation in primary mouse hepatocytes in the 
presence or absence of primary KC.  The data indicate that KC, activated by the 
saturated fatty acid palmitate, produce PGE2, which directly acts on hepatocytes to 
decrease lipid oxidation.  Finally, mice lacking the gene for mPGES-2 become more 
obese than their wild type counterparts when placed on a high fat diet.  
2.3 MATERIALS AND METHODS 
2.3.1 Hepatocyte isolation and cell culture  
Primary mouse hepatocytes were isolated using a non-recirculating in situ collagenase 
perfusion technique, modified as previously described [128].  A buffered salt solution 
containing 0.95g/L EGTA was perfused, in situ, through the inferior vena cava, exiting 
the portal vein (retrograde to blood flow), to remove any blood contained in the liver.  
Subsequently, a 0.2mg/mL collagenase solution (type IV; Sigma C-5138, St. Louis, MO) 
was perfused to release hepatocytes and immune cells from the connective tissue.  
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Livers were agitated to release cells, then hepatocytes were separated from other cells 
using a series of 40 x g spins and a 30% percoll gradient.  Resulting hepatocytes were 
counted, assessed for viability using Trypan Blue exclusion, resuspended at 0.5x106 
live hepatocytes/mL, then plated on type I collagen coated 6- or 24-well plates (Falcon 
35-3046 or 35-3047, respectively; collagen = Sigma C-8919) at a density of 1.2x106 
hepatocytes/6-well well or 2.5x105 hepatocytes/24-well well.  Non-attached cells were 
removed after 1 hour (45 min if in 24-well plates), by washing with RPMI 1640 
containing 10% heat inactivated FBS, 4.5g/L glucose, 1mM sodium pyruvate, 0.1mM 
nonessential amino acids, 2mM L-glutamine, 100U/mL penicillin, and 100ug/mL 
streptomycin [high glucose (HG) cRPMI].  Treatment media, containing fatty acid plus or 
minus 10µM indomethacin, 1mM carbachol, various doses of PGE2, or 500ng/mL LPS, 
was prepared in HG cRPMI, and replaced the wash at the start of culture. 
2.3.2 Kupffer cell isolation and cell culture 
Liver mononuclear cells were isolated, modified as previously described [91].  The 
supernatants from the non-percoll hepatocyte centrifugations were centrifuged at 40 x g 
for 5 min, and then the resultant supernatants were centrifuged at 375 x g.  The cell 
pellet containing non-parenchymal cells was resuspended in 2.7mL cRPMI (as above 
but with 2.0g/L glucose) and mixed with 7.3mL 30% Histodenz (Sigma D-2158).  The 
resulting suspension was split into two aliquots of 5mL and layered under 5mL of 
cRPMI, and centrifuged at 1425 x g for 20 min at 22°C with no brakes.  Mononuclear 
cells remaining at the interphase between the two layers were collected and plated in 
cRPMI on 6-well plates (Falcon) or on trans-well inserts, as needed.  Kupffer cells (KC) 
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were allowed to adhere to plates or inserts for 1 hour, then plating media was removed, 
together with non-adherent mononuclear cells, and replaced with treatment media.  
Additionally, control inserts plated with only cRPMI were also placed in the incubator for 
1 hour, at the end of which the cRPMI was replaced with treatment media. 
2.3.3 Hepatocyte and KC co-culture 
Liver mononuclear cells were plated in Transwell Permeable Supports (Corning, 
Corning, NY) at a density 1/3 that of the hepatocytes (thus, 4x105 in 6-well inserts or 
8.3x104 in 24-well inserts).  Once KC attach, 2mL HG cRPMI containing 0.4mM 
palmitate or BSA vehicle control was added to the insert, and 2mL treatment media was 
added directly to the hepatocytes (200uL to the insert and 800uL directly to hepatocytes 
in 24-well plates).  Hepatocytes and KC were co-cultured for 19 hours, then analyzed 
for palmitate oxidation, PGE2 production, or RT-PCR. 
2.3.4 Mouse primary hepatocyte palmitate oxidation 
After 14 hours in culture in the presence or absence of 0.4mM palmitate and the 
presence or absence of 500ng/mL LPS, 2.5uCi/mL palmitic acid [9,10-3H(N)] (Perkin 
Elmer, Boston, MA) and palmitate to a level of 0.4mM were added to each well for 5 
hours.  Palmitate oxidation was assessed by measuring the quantity of tritiated water 
released into the medium, as previously described [129].  The monolayers were washed 
twice with ice-cold PBS and collected in 1N NaOH for determination of protein content. 
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2.3.5 Quantification of cytokine production 
Cell culture supernatants from various cell treatments were collected after 19 hours of 
culture, and assayed for the presence of 23 cytokines/chemokines (IL-1α, 1β, 2, 4, 5, 6, 
10, 12(p40), 12(p70), 13, and 17, TNFα, IFN-γ, IP-10, CXCL1, MCP-1, M-CSF, MIG, 
MIP-1α, MIP-1β, MIP-2, RANTES, and GM-CSF) using a Milliplex Luminex Kit 
(Millipore), according to the manufacturer’s instructions.   
2.3.6 PGE2 EIA 
PGE2 released into the cell culture medium by co-culture or monoculture was measured 
using a commercial kit (by EIA; Cayman Chemical, Ann Arbor, MI) according to the 
protocol provided by the manufacturer.   
2.3.7 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
For analysis of gene expression, total RNA was isolated from liver or adipose tissue 
using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions.  RT-PCR was carried out using gene specific primers, SYBR green master 
mix (Bio-Rad, Hercules, CA) and an Applied Biosystems Prism 7300 Real-Time PCR 
System, as previously described [63].  Fold change in mRNA expression was 
determined using the ΔΔcT method, with all genes normalized to β-actin. 
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2.3.8 Western blot 
Hepatocytes plated in 6-well plates were cultured in the presence of 0.4mM palmitate in 
the presence or absence of KC, or the presence or absence of PGE2.  After 18 hours in 
culture, cell lysates were harvested and prepared using standard Western blotting 
procedures [anti-acetyl-CoA carboxylase (Cell Signaling #3662) and anti-phospho-
acetyl-CoA carboxylase (Ser79) (Cell Signaling #3661)].  Immunoblots were quantified 
by densitometry using ImageJ Software.   
2.3.9 Mouse primary hepatocyte palmitate esterification and triglyceride 
accumulation 
Hepatocytes plated in 6-well plates were cultured in the presence of 0.4mM palmitate in 
the presence or absence of KC, or the presence or absence of PGE2.  After 16 hours of 
culture, 2.5uCi/mL palmitic acid [9,10-3H(N)] was added to the esterification plates for 
two hours.  Hepatocyte monolayers were washed twice with an excess of ice-cold PBS, 
then treated briefly with 12.5% trypsin-EDTA, and harvested in 1mL of ice cold PBS.  
Cells were pelleted, and analyzed for lipids and protein, as previously described [130]. 
2.3.10  Animal care and maintenance 
Male Ptges2-/- (KO, lacking mPGES-2) and age matched wild type C57BL/6 (WT) mice 
were obtained from Jackson Laboratories.  KO mice were generated using 129S 
embryonic stem cells, injected into C57BL/6 blastocysts, and the resulting chimeras 
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were backcrossed to pure C57Bl/6 mice for 12 generations.  Prior to the experiments, 
mice were maintained on a constant 12-h light:12-h dark cycle with free access to water 
and ad libitum fed with a standard chow diet.  All procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh, 
and were in accordance with the National Research Council's Guide for the Care and 
Use of Laboratory Animals. 
2.3.11  In vivo experimental design 
Ptges2-/- (KO) and age-matched wild type (WT) control mice (n=8 in each group) were 
fed ad libitum with a high fat diet (HFD; 44% calories from fat – 19% lard, 1% corn oil) 
from Harlan Teklad for 10 weeks.  Mice and food were weighed weekly during the 
course of the experiment.  Also, mice underwent an analysis of insulin sensitivity using 
glucose tolerance, metabolic rate using the CLAMS (Comprehensive Laboratory Animal 
Monitoring System, OH), and body composition using a Lunar PIXImus densitometer 
(Lunar, Madison, WI).  Whole-body scans, with exclusion of the head, were analyzed for 
fat and lean masses using the manufacturer’s software.  At the conclusion of this period, 
blood and tissues were isolated, flash frozen and stored at –80°C until analysis. 
2.3.12  Glucose tolerance tests (GTT)  
For the GTT, 6-hour fasted mice were injected i.p. with 1.5 g/kg glucose.  Blood was 
sampled from the tail vein every 15 minutes for 2 hours post-injection and glucose was 
measured using an Ascensia Elite glucometer (Bayer, Mishawaka, IN). 
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2.3.13  Tissue and plasma measurements 
Liver and plasma triglycerides (TG) were determined as previously described [48,130].  
Fasting blood glucose represents t=0 of the GTT (prior to injection of glucose). 
2.3.14  Statistical analysis 
Data are expressed as means ± SE.  Statistical significance was determined by t-test 
and, where appropriate, analysis of variance (repeated measures or one-way ANOVA; 
Bonferroni's post-hoc test) was performed using the PASW Statistics program (Chicago, 
IL).  Statistical significance was assumed at p ≤ 0.05. 
2.4 RESULTS 
2.4.1 Palmitate-activated Kupffer cells (KC) decrease hepatocyte palmitate 
oxidation 
Previous studies have reported decreases in rat hepatocyte palmitate oxidation when 
co-cultured with KC [91].  We first sought to confirm these findings in mice, as proof of 
principle, and then extend these observations, to determine which genes in the KC may 
be required for the effects seen.  Consistent with previous studies, there was a 
decrease in hepatocyte palmitate oxidation when co-cultured with KC (Figure 3A).  This 
effect was only present when cells were co-cultured overnight in the presence of 
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palmitate, not LPS (Figure 3A).  Additionally, there was no difference in palmitate 
oxidation between hepatocytes alone and when TLR4-null KC were co-cultured with 
hepatocytes (Figure 3B).   
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Figure 3 - Palmitate-activated Kupffer cells decrease hepatocyte palmitate oxidation. 
 
(A) Primary hepatocytes from C57Bl/6 mice were cultured overnight in the presence of either 
0.4mM palmitate or 500ng/mL LPS and the presence or absence of KC.  (B) Alternatively, wild 
type hepatocytes were cultured in the presence of wild type or TLR4 knock out KC.  Palmitate 
oxidation was measured via tritiated water exchange, as described in Methods.  Results are 
presented as the means±SE for five (Panel A) or four (Panel B) experiments performed in 
triplicate.  *p<0.05, **p<0.005, ***p<0.0005. 
2.4.2 Cytokine production from KC and hepatocytes in the presence of palmitate. 
Given that KC can alter hepatocyte palmitate oxidation in a co-culture setting, the 
responsible agent must be a soluble factor that is passed between the two cell types.  
Our first class of candidate molecules was cytokines, as they are soluble proteins 
produced in large quantities by macrophages upon activation, and act in autocrine and 
paracrine fashion [131].  To determine if cytokines were altered by the presence of 
palmitate, we treated KC or hepatocytes in monoculture with 0.4mM palmitate or vehicle 
control, and performed Luminex analysis on the supernatants 18 hours later.  While we 
saw a robust response after LPS treatment, overnight culture in the presence of 
palmitate did not change KC production of the pro-inflammatory cytokines TNFα or IFN-
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γ, nor the production of the anti-inflammatory cytokine IL-10 (Figure 4A-C).  There was, 
however, a slight increase in the production of IL-1β (Figure 4D) in response to 
palmitate, without a concomitant increase in IL-6 (data not shown).  Furthermore, there 
was in increase in KC production of MCP-1 (Figure 4E), and a small, but significant, 
increase in hepatocyte production of the chemokine CXCL1 (Figure 4F).   
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Figure 4 - Cytokine production by Kupffer cells (KC) and hepatocytes in the presence of 
palmitate. 
 
Kupffer cells or hepatocytes were cultured overnight in the presence or absence of 0.4mM 
palmitate or the presence or absence of LPS.  Cell culture supernatants were collected and 
analyzed by Luminex.  Results are presented as the means±SE for an n=4 in KC and an n=3 in 
hepatocytes.  *p<0.05 
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2.4.3 KC produce prostaglandin E2 (PGE2) in response to palmitate  
Our search for the soluble factor responsible for the detrimental effects of KC on 
hepatocyte β-oxidation led to another suitable candidate, which has the added bonus of 
being a small lipid (and thus particularly pertinent in the setting of obesity), namely the 
eicosanoid PGE2.  In the presence of palmitate, but not in the vehicle control (BSA), the 
co-culture of hepatocytes and KC exhibits a roughly three-fold increase in the 
production of PGE2 (Figure 5A), which is derived almost completely from the KC 
(Column #6).  We next tested whether PGE2 in the culture media was sufficient to cause 
a decrease in hepatocyte palmitate oxidation.  We treated hepatocyte monocultures 
with increasing doses of PGE2 and saw a decrease with as little as 10pM PGE2 (Figure 
5B).  Importantly, the decrease in palmitate oxidation was not due to a loss of cell 
viability as measured by Alamar Blue fluorescence (Figure 5C).  Additionally, we 
performed a time course experiment to determine the length of PGE2 exposure time 
required in order to cause this decrease in palmitate oxidation.  Our data indicate that 
this effect is still present with as little as 5 hours of PGE2 treatment (Figure 5D).   
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Figure 5 - Prostaglandin E2 (PGE2) effects on hepatocyte metabolism.   
 
(A) Hepatocytes (Heps) and KC were cultured separately or co-cultured overnight, as described 
in Methods, after which cell culture media was collected and analyzed for PGE2 concentration.  
(B&C) Hepatocyte monocultures were treated with increasing doses of PGE2 and analyzed for 
palmitate oxidation (Panel B) or cell viability (Panel C).  (D) Hepatocytes were cultured overnight 
in the presence of 0.4mM palmitate, and then treated with 1nM PGE2 or 100mM PGE2 for the 
times indicated.  They were subsequently analyzed for palmitate oxidation.  Results are 
presented as the means±SE for a minimum of 3 experiments performed in triplicate.  *p<0.05, 
**p<0.005, ***p<0.0005. 
 
2.4.4 EP receptor subtype expression and mechanism  
Given that PGE2 is sufficient to cause a decrease in hepatocyte palmitate oxidation, we 
next asked which receptor might be responsible for this action.  First, we performed RT-
PCR to determine which of the EP receptor subtypes are expressed in mouse 
hepatocytes and found EP1 to be the most highly expressed of the PGE2 receptor 
subtypes (Figure 6A), although primer efficiencies are required before this strict 
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comparison can be made.  To test whether action downstream of EP1 is involved in the 
interaction between KC and hepatocytes, we treated hepatocyte monocultures with 
carbachol, a pan-muscarinic receptor agonist, which increases the intracellular 
concentrations of calcium via the M1, M3, & M5 receptors, to determine whether an 
increase in intracellular calcium will decrease β-oxidation, thus mimicking action through 
EP1.  As the data shows, 1mM carbachol is able to replicate this effect (Figure 6B).   
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Figure 6 - E-prostanoid receptor expression and involvement of calcium signaling. 
(A) Primary mouse hepatocytes were cultured overnight in the presence or absence of 100mM 
PGE2.  RNA extracts were prepared and RT-PCR was performed, as described in Methods.  (B) 
Primary mouse hepatocytes were cultured in the presence of 0.4mM palmitate and the presence 
or absence of 1mM carbachol.  Results are presented as the means±SE for a minimum of three 
experiments performed in triplicate.  *p<0.05, ***p<0.0005. 
 
2.4.5 Inhibitors of PGE2 action alter palmitate oxidation 
We next tested the ability of indomethacin, a non-selective COX-1/COX-2 inhibitor, to 
block the effect of KC on hepatocyte metabolism.  10µM indomethacin is able to reverse 
the decrease in oxidation caused by the presence of KC (Figure 7A).  We also 
attempted to test the case where KC were unable to produce PGE2 by utilizing KC from 
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mice lacking the gene encoding microsomal prostaglandin E2 synthase-2 (Ptges2-/-).  
Interestingly, in this circumstance, we did not see the same protection against the 
decrease in hepatocyte palmitate oxidation (Figure 7B); however, we discovered that 
these cells were still producing PGE2 in response to palmitate (Figure 7C).   
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Figure 7 - Inhibitors of PGE2 alter hepatocyte metabolism.   
(A) Primary mouse hepatocytes were co-cultured with KC overnight in the presence or absence 
of 10uM indomethacin and palmitate oxidation was measured.  (B) Hepatocytes were cultured in 
the presence of wild type or Ptges2 knock out KC.  Palmitate oxidation was measured.  Results 
are presented as the means±SE for four experiments performed in triplicate.  (C) Wild type (WT – 
n=3) or Ptges2 knock out (KO – n=2) KC were cultured overnight in the presence or absence of 
palmitate.  Cell culture media was collected and analyzed for PGE2 concentration.  *p<0.05, 
**p<0.005. 
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2.4.6 Intracellular mechanisms of altered metabolism 
We postulated that the changes occurring within the hepatocyte in response to PGE2 
that resulted in decreased palmitate oxidation could be a gene transcription change, a 
protein translation change, or a biochemical change, such as protein phosphorylation.  
First, we performed RT-PCR on hepatocytes treated with PGE2, and found that these 
effects are not due to alteration of gene expression of key lipid metabolism genes 
(PPARα, PGC-1α, SREBP1c, SCD-1, DGAT1, Foxo1, ACC1; Figure 8A).  Interestingly, 
the Western Blot of total and phosphorylated ACC (Figure 8B) and densitometry 
quantification (Figure 8C) indicate that phosphorylation of ACC, in the presence of 
palmitate, decreases.  ACC is activated in the dephosphorylated state; therefore, this 
key lipogenic enzyme could be more active in response to treatment with PGE2, 
consistent with the finding of decreased lipid oxidation (a lipolytic process).   
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Figure 8 - Gene expression and ACC activation in response to PGE2. 
(A) Primary mouse hepatocytes were co-cultured with KC overnight in the presence or absence 
of 100uM PGE2.  RNA extracts were prepared and RT-PCR was performed, as described in 
Methods.  (B) Western blots of total and phosphorylated ACC in the presence or absence of 
0.4mM palmitate and the presence or absence of 1nM or 100mM PGE2.  (C) Densitometry of 
Western blots shown in (B).   
 
2.4.7 KC and PGE2 effects on lipid buildup 
Given the changes we see in lipid catabolism, we became interested in how co-culture 
with KC and administration of PGE2 would affect the opposing processes of lipid 
synthesis.  We tested both palmitate esterification (Figure 9A&B) and triglyceride (TG) 
accumulation (Figure 9C&D) in mouse hepatocytes.  Surprisingly, treatment with PGE2 
did not alter the esterification (Figure 9B), and co-culture of KC with hepatocytes acts to 
decrease palmitate esterification (Figure 9A), contrary to our expectations given our 
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ACC phosphorylation data.  Additionally, TG accumulation within the hepatocyte trends 
towards increasing in response to both PGE2 treatment and incubation with KC.   
 
 
Figure 9 - PGE2 and KC effects on palmitate esterification and TG accumulation. 
(A) Primary mouse hepatocytes were co-cultured with KC overnight in the presence of 0.4mM 
palmitate or mono-cultured in the presence or absence of PGE2.  Esterification of fatty acids was 
measured for an n=3 experiments performed in duplicate (PGE2 treatment) or triplicate (KC co-
culture), as described in Methods.  (B) Primary mouse hepatocytes were co-cultured with KC 
overnight in the presence of 0.4mM palmitate or mono-cultured in the presence or absence of 
PGE2.  Accumulation of TG within the hepatocytes was measured for an n=2 experiments 
performed in duplicate (PGE2 treatment) or triplicate (KC co-culture), as described in Methods. 
*p<0.05. 
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2.4.8 Knockout of prostaglandin E2 synthase-2 exacerbates the metabolic 
disturbances of obesity 
Given the effects of PGE2 on hepatocyte metabolism, we became interested in whether 
a mouse unable to produce PGE2 upon challenge, would be protected from the 
metabolic disturbances of obesity.  We placed Ptges2-/- and wild type controls on a HFD 
for 10 weeks and measured weight gain (Figure 10A), adiposity (Figure 10B), glucose 
tolerance (Figure 10C&D), fasting blood glucose (Figure 10E) and liver triglyceride 
buildup (Figure 10F).  Weight gain was identical for much of the duration of the diet, 
however at 6 weeks, a gradual deviation started to occur, which did not reach statistical 
significance (Figure 10A).  Additionally, whole body knock out of Ptges2 caused a 
substantial elevation in the fat mass and percent fat (Figure 10B).  Glucose tolerance, 
fasting blood glucose and liver triglycerides were not altered in these animals.  
Importantly, analysis of serum of WT and Ptges2 mice demonstrated that Ptges2 mice 
have lower concentrations of circulating PGE2 (data not shown). 
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Figure 10 - Ptges2 KO mice gain more fat mass on a HFD. 
Wild-type (WT) and Ptges2 null (KO) mice were placed on a high fat diet (HFD) and weight gain 
was monitored weekly (Panel A).  After 8 weeks on HFD, mice underwent glucose tolerance tests 
(GTT and Area Under the Curve, Panels C&D).  After 1 week for recovery, body composition was 
measured by DXA scan (Panel B).  Fasting blood glucose (Panel E) and liver triglycerides (Panel 
F) were assessed in WT and KO mice as described in Methods.  Results are presented as the 
means±SE for at least 7 animals in each group.  *p<0.05. 
 
2.5 DISCUSSION  
The major goal of this study was to address the potential role of Kupffer cells (KC) in the 
pathogenesis of one of the hallmarks of overnutrition, obesity, and the metabolic 
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syndrome, namely the accumulation of fat in the liver.  A number of novel observations 
are presented which expand on the known KC-mediated effects on hepatocyte 
metabolism and address the impact of the immune system on nutrient utilization.  The 
data demonstrate that 1) hepatocytes exhibit lower rates of palmitate oxidation when co-
cultured in the presence of KC, 2) co-culturing these cells in the presence of 
indomethacin abrogates this effect, 3) KC are activated by palmitate to produce PGE2 
and 4) genetic deletion of the constitutive PGE2 synthase (mPGES-2, the Ptges2 gene 
product) may exacerbate adiposity when mice are placed on a HFD.  We were 
motivated by previous reports that have suggested an involvement of the pro-
inflammatory cytokine TNFα, as well as the eicosanoids in metabolism.  These studies 
have demonstrated that TNFα is elevated in the adipose tissue of human obesity and 
insulin resistance [9,15], mediates the induction of insulin resistance in 3T3-L1 
adipocytes [57] and contributes to the development of insulin resistance in the Zucker 
fatty rat model of obesity [15].  Additionally, prostaglandins have been implicated in 
nutrient metabolism.  Specifically, PGE2 influences glycogenolysis [119,121,122] and 
glycogen synthesis [124], as well as gluconeogenesis [118].  Of particular interest to the 
work described here, PGE2 inhibits lipid synthesis [127] and also inhibits hormone-
stimulated β-oxidation [126].  Importantly, no previous studies have been undertaken 
which analyzed mouse primary hepatocyte lipid oxidation in response to co-culture with 
KC, nor have other studies described the response of cultured mouse hepatocytes to 
PGE2.   
 A number of seminal studies have now established that macrophage numbers 
and activation increase in the hypertrophic adipose tissue abundant in obesity 
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[82,84,85].  To date, however, much less is known about the overnutrition response of 
macrophages in other insulin sensitive tissues.  In the liver, resident Kupffer cells 
account for over 5% of the total cell population and are located in the sinusoids where 
they are well positioned to sample nutrients and other inflammatory mediators delivered 
to the liver directly from both the gut (via the portal vein) and systemic circulation (via 
the hepatic artery) [132].  Thus, KC are among the first cells to recognize and respond 
to potential macrophage-activating signals.  
The nature of these signals in the setting of overnutrition is still not fully 
understood.  We have demonstrated previously that co-culture of rat primary 
hepatocytes with LPS-activated KC decreases palmitate oxidation [91].  Indeed, a 
number of recent studies have demonstrated that an increase in circulating LPS may 
mediate the effects of overnutrition [12-14].  Thus, circulating LPS is elevated in obese 
patients and can cause the release of pro-inflammatory cytokines from cultured human 
adipocytes [12].  Additionally, a continuous infusion of LPS to levels reported in obesity 
induces steatosis, insulin resistance and obesity [13], while treatment of high fat fed 
mice with antibiotics to lower endotoxemia improves insulin sensitivity and steatosis 
[14].  Of note, however, in the present study we have demonstrated that LPS is not 
required to induce a reduction in hepatocyte palmitate oxidation when co-cultured with 
KC; i.e., the presence of the saturated fatty acid itself is sufficient to start the cascade 
resulting in decreased lipid breakdown.  Furthermore, we have presented data that 
reveal a number of differences between the response to LPS and the response to 
saturated fatty acids.  As shown in Figure 3A, only when palmitate is present overnight 
did the addition of KC to hepatocytes lower the rate of β-oxidation.  Additionally, LPS 
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induced TNFα and IFNγ production from mouse KC, but palmitate did not.  These data 
are particularly interesting in light of the proposed mechanism by which these two 
molecules exert their functions on effector cells of the immune system.   
Toll like receptor (TLR) 4, the classical receptor for LPS, has also recently been 
described as the receptor for saturated free fatty acids [37-39].  Specifically, saturated 
fatty acids activate NF-κB and induce the expression of COX-1 in macrophages [37,43]; 
TLR4 deficient mice are protected against insulin resistance and steatosis when placed 
on a HFD [39]; and knock out of TLR4 protects mice against the skeletal muscle insulin 
resistance induced during acute lipid infusion [38,63].  Furthermore, we have 
determined that TLR4 is required in the KC to decrease hepatocyte palmitate oxidation 
(Figure 3B).  It is important to note that we have not ruled out LPS being involved in the 
modulation of hepatocyte lipid metabolism, but rather have presented evidence that 
saturated fatty acids or, potentially, a combination of LPS and fatty acids may be 
responsible for KC mediated alterations in lipid breakdown in the setting of obesity. 
The current study expands on recent reports that implicate KC in the modulation 
of hepatocyte lipid metabolism [89-91].  These other studies have all linked the pro-
inflammatory, M1 or ’classical’ activation of macrophages in the pathogenesis of the 
metabolic disturbances of obesity.  Thus, mice with a myeloid-specific depletion of 
PPARδ, a transcription factor integral in the M2 or ‘alternative’ activation of 
macrophages (i.e. traditionally thought of as anti-inflammatory), exhibit higher levels of 
inflammation, steatosis, and insulin resistance [89,90].  Furthermore, hepatocytes from 
these animals exhibit elevated expression of genes involved in lipid synthesis, while the 
expression of genes involved in oxidation remains unchanged [89].  Our group has 
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recently shown that rats depleted of KC by injection of gadolinium chloride (GdCl3) are 
protected against the development of insulin resistance and steatosis when placed on a 
HFD.  Additionally, M1 polarized KC induce alterations in metabolic pathways in rat 
hepatocytes which promote the development of steatosis (decrease palmitate oxidation, 
and increase palmitate esterification and triglyceride accumulation); an effect which 
appears to require the pro-inflammatory cytokine TNFα [91].  Notably, in the current 
study, which utilized a mouse hepatocyte/KC co-culture system, we recapitulated the 
KC-mediated decrease in hepatocyte fatty acid oxidation, but we did not observe the 
same increase in TNFα as was seen in the rat system.  It is possible that factors such 
as the animal model utilized (mouse versus rat), stimulus employed (LPS versus 
saturated fatty acid) or materials used (6- versus 24-well plates or trans-well inserts, as 
detailed as possible in Appendix A) may have masked changes. However, a more likely 
explanation is that the Kupffer cells mediate alterations in hepatocyte metabolism by 
signals other than cytokines.  Indeed, the studies reviewed above do not discuss other 
potential mediators of inflammation and the effects those molecules may exert on 
hepatocyte metabolism.  The current study explores the hypothesis that another 
inflammatory mediator, namely the eicosanoid PGE2, is also involved in the regulation 
of metabolism. 
Previous studies have generated a rather controversial picture of the effects of 
PGE2 on nutrient metabolism.  According to some studies, PGE2 inhibits glucagon-
mediated glycogen phosphorylase activity [119,133], and therefore decreases 
glycogenolysis [121] by inhibiting glucagon stimulated elevations in cAMP 
concentrations within the hepatocyte [126].  Utilizing the same system, others have 
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found that PGE2 also stimulates glycogen phosphorylase activity, and therefore 
enhances glycogenolysis, via calcium signaling [117,134,135].  These differences were 
later ascribed to differences in receptor activation; the glycogenolytic effect resulting 
from engaging the EP1 receptor and subsequent Gq activation, and the anti-
glycogenolytic effect resulting from EP3 receptor activation with downstream effects due 
to Gi action [119].  Neyrinck and colleagues [127] have shown that removal of KC-
derived PGE2, via GdCl3 injection into rats, increases lipid accumulation within the 
hepatocytes of liver sections.  Furthermore, they demonstrate that rates of lipid 
synthesis decrease, esterification does not change and oxidation increases in cultured 
rat hepatocytes in response to 48 hour PGE2 treatment.  They, therefore, conclude that 
PGE2 serves a protective role against the development of steatosis.  Conversely, Brass 
and colleagues [126] demonstrated that PGE2 decreases glucagon-stimulated palmitate 
oxidation and Björnsson and colleagues [125] determined that PGE2 inhibits VLDL 
secretion, both supporting a pathogenic role for PGE2 in the development of steatosis.  
These apparently contradictory results are exemplified by findings that PGE2, classically 
the quintessential pro-inflammatory lipid mediator, is now attributed both pro- and anti-
inflammatory functions [115].   
The current study implies a role for the eicosanoid PGE2 in the pathogenesis of 
the deregulated lipid metabolism caused by overnutrition.  Thus, PGE2 is produced by 
KC in response to elevated saturated fatty acid, treatment of hepatocyte/KC co-cultures 
with indomethacin restores oxidative capacity to levels comparable to those seen with 
hepatocytes in the absence of KC, and exogenous treatment of hepatocytes with PGE2 
decreases the rate of lipid oxidation.  Our findings that PGE2 decreases palmitate 
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oxidation are in opposition to the findings of Neyrinck et al. [127].  This may be due to 
differences in the model system used (mouse versus rat), exposure time to PGE2 (19 
hours versus 48 hours), or method of oxidation measurement (14CO2 versus 3H2O 
quantification).  Further studies would be required to discern the cause of this 
discrepancy.  Similar to Neyrinck et al. [127], we found no alteration of palmitate 
esterification in response to PGE2 treatment, however we did observe a decrease in 
response to the addition of KC, indicating that the KC-mediated regulation of 
esterification may occur by a mechanism distinct from PGE2 or cytokines.  In 
conclusion, these data clearly demonstrate that PGE2 is involved in the KC effects on 
hepatocyte palmitate oxidation.   
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3.0  CHAPTER 3 – THE ROLE OF EXOGENOUS ADMINISTRATION OF 
DENDRITIC CELLS ON THE METABOLIC DISTURBANCES OF OBESITY 
3.1 ABSTRACT 
Dendritic cells (DC), the professional antigen presenting cells in the body and the cells 
responsible for directing both innate and adaptive immunity, have recently been 
implicated in the generation of inflammation and the subsequent metabolic changes 
seen in type II diabetes mellitus and obesity.  In this study, we describe a previously 
unknown role for DC in the determination of body composition and insulin sensitivity in 
the setting of overnutrition.  
To address this question, bone marrow-derived dendritic cells (BMDC) were 
generated and injected weekly into syngeneic C57Bl/6 mice consuming a high fat diet 
(HFD).  Weight gain and caloric intake were measured weekly, and adiposity, metabolic 
rate, activity, insulin sensitivity, steatosis and immunophenotype were assessed at the 
end of the seven-week diet.   
Injection of immature BMDC (iDC) decreased adiposity of mice consuming a 
HFD, but bone marrow-derived macrophages (BMDM) and LPS-activated BMDC did 
not.  Basal metabolic rate and activity were unchanged between the groups.  iDC 
injection caused infiltration of mononuclear cells predominantly in the white adipose 
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tissue, an effect that was independent of diet.  This infiltrate was skewed towards the 
anti-inflammatory TH2 phenotype.  iDC injection did not alter liver triglyceride buildup or 
plasma triglyceride levels; however, mice receiving iDC exhibited improved insulin 
sensitivity by glucose tolerance test. 
These data implicate DC in the development of the metabolic disturbances of 
obesity.  Specifically, DC may be involved in determining how our bodies respond to 
caloric challenge in terms of depositing fat and preventing insulin resistance. 
3.2 INTRODUCTION 
Obesity and type II diabetes mellitus coincide with a state of chronic, low-grade 
inflammation, which has been implicated in the pathogenesis of insulin resistance and 
dyslipidemia.  Many studies have implicated elevations of adipose tissue macrophages 
(ATM) in the development of this inflammatory state and the concomitant systemic 
changes seen in obesity [81-85]; however, there continues to be interest in determining 
the potential role of other immune cells in altering metabolism.  For example, CD8+ T 
cells [79], CD4+ T cells [136], regulatory T cells [78] and B cells [80] have all been 
shown to play a role in the development of the metabolic disturbances of obesity.  In this 
regard, dendritic cells (DC) are bone marrow-derived professional antigen presenting 
cells (APCs) that are key in the initiation and modulation of both innate and adaptive 
immune responses [92-94].  Studies have shown that cells expressing the classical DC 
marker, CD11c, increase in the adipose tissue of obese mice [97,100]; however, this 
has been in the context of describing elevations in ATM content.  Our group has 
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recently discovered that a substantial proportion of the CD11c+ cells in adipose tissue 
were DC and that these cells promoted the accumulation of macrophages in obese 
adipose tissue (Stefanovic-Racic, et al., submitted).  We have also found that Flt3L 
knock out mice, which lack DC, are completely protected from weight gain, insulin 
resistance and steatosis when placed on a high fat diet (O’Doherty, unpublished 
observations).  While these findings indicate that DC are associated with the elevated 
inflammatory state and metabolic disturbances of obesity, they do not assign a causal 
role to DC in these processes.  The current study tests the hypothesis that DC are 
directly involved in the development of obesity and the subsequent metabolic changes 
when mice are placed on a HFD.  Our data demonstrate that exogenous administration 
of immature bone marrow-derived DC (BMDC), but not LPS-activated BMDC or BMDM, 
decreases the weight gain and improves the insulin sensitivity of mice eating a HFD.  
3.3 MATERIALS AND METHODS 
3.3.1 Animal care and maintenance 
Male wild type C57BL/6 mice were obtained from Jackson Laboratories.  Prior to 
experiments, mice were maintained on a constant 12-h light:12-h dark cycle with free 
access to water and ad libitum fed with a standard chow diet.  All procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the University 
of Pittsburgh, and were in accordance with the National Research Council's Guide for 
the Care and Use of Laboratory Animals. 
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3.3.2 Experimental design 
At 7 weeks of age, wild type C57BL/6J mice received their first injection i.p. and were 
started on an ad libitum fed high fat diet (HFD; 44% calories from fat, 19% Lard, 1% 
Corn Oil) from Harlan Teklad or kept on a standard chow (SC) diet (n=7 in SC groups, 
n=10-12 in HFD groups).  During the course of the experiment, mice received a single 
injection of 1x106 bone marrow-derived dendritic cells (BMDC) or bone marrow-derived 
macrophages (BMDM), every week for 6 weeks.  Mice and food were weighed weekly 
over the course of the experiment.  During this period, mice underwent an analysis of 
insulin sensitivity using glucose tolerance tests, metabolic rate using the CLAMS 
(Comprehensive Laboratory Animal Monitoring System, OH), and body composition 
using a Lunar PIXImus densitometer (Lunar, Madison, WI).  Whole-body scans, with 
exclusion of the head, were analyzed for fat and lean masses using the manufacturer’s 
software.  At the end of this period, one full week after the sixth injection, blood and 
tissues were isolated for flow cytometric analysis or triglyceride measurements, or flash 
frozen and stored at –80°C until analysis.   
3.3.3 Generation and purification of BMDC 
BMDC were prepared, with modifications as previously described [101].  In brief, a 
single cell suspension of bone marrow cells was depleted of I-A+ cells, B cells and T 
cells via incubation with monoclonal antibodies and complement treatment.  Remaining 
cells were cultured in serum free AIM-V medium (Gibco 12055) containing 5ng/mL GM-
CSF for 5 days.  On day two, 50% of the medium was replaced with fresh AIM-V with 
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GM-CSF.  On day 5, half of the cultured cells were treated with 1ug/mL LPS (Sigma L-
3012) for two hours to generate activated BMDC (LPS-DC).  Untreated, immature 
BMDC (iDC) and LPS-DC were purified using CD11c magnetic beads (Miltenyi Biotec, 
Auburn, CA), according to the manufacturer’s instructions.   
3.3.4 Generation and culture of bone marrow-derived macrophages (BMDM) 
BMDM were generated from the culture of bone marrow progenitors, as previously 
described [137].  Briefly, bone marrows, isolated from femur and tibia, were depleted of 
red blood cells using Red Blood Cell Lysing Buffer (Sigma R7757).  Cells were plated at 
a density of 1x107/15cm dish (day 0) in 20mL DMEM supplemented with 20% heat-
inactivated FBS, 1mM sodium pyruvate, 2mM L-glutamine, 100U/mL penicillin, 
100ug/mL streptomycin and 30% L-cell supernatant, until confluent.  Differentiation 
media was replaced 3-4 days after initial plating, then used for injections on day 7.   
3.3.5 Glucose tolerance tests (GTT)  
For the GTT, 6-hour fasted mice were injected i.p. with 1.5 g/kg glucose. Blood was 
sampled from the tail vein every 15 minutes for 2 hours post-injection and glucose was 
measured using an Ascensia Elite glucometer (Bayer, Tarrytown, NY).   
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3.3.6 Tissue collection and generation of single mononuclear cell suspensions 
One week after the 6th injection (7 weeks total on HFD), the mice were sacrificed, as 
follows: blood was collected by cardiac puncture, then 10mL PBS was perfused through 
the liver from the proximal IVC, one of the smaller lobes of the liver was then removed 
and flash frozen for triglyceride measurements.  Subsequently, 5mL of a 1mg/mL 
solution of collagenase (type IV; Sigma C-5138, St. Louis, MO) was perfused to release 
hepatocytes and non-parenchymal cells from the surrounding connective tissue.  
Spleen and epididymal and renal fat pads were collected as well.  Livers were agitated 
to release cells, then incubated at 37°C 5% CO2 for 30 min.  Resulting digest was 
passed over a 70um cell strainer, hepatocytes were removed with one 45 x g 
centrifugation, and mononuclear cells in the supernatants were pelleted, then isolated 
on an 8% Histodenz gradient.  Fat pads were combined and digested in a 1mg/mL 
collagenase solution, then passed over a 100um cell strainer.  Red blood cells were 
lysed twice using Red Blood Cell Lysing Buffer (Sigma R7757).  Splenocytes were 
isolated by forcing spleens through a 40um strainer and subsequently lysing the red 
blood cells using Red Blood Cell Lysing Buffer (Sigma R7757). 
3.3.7 Quantification of cytokine production 
Tissue mononuclear cells were plated at a density of 1x106/mL in 96-well plates (Falcon 
35-3077) and treated with PMA/ionomycin (PMA = 10ng/mL, ionomycin = 500ng/mL).  
Cell culture supernatants were collected after 24 hours of treatment, and assayed for 
the presence of 23 cytokines/chemokines (IL-1α, 1β, 2, 4, 5, 6, 10, 12(p40), 12(p70), 
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13, 17, TNFα, IFN-γ, IP-10, CXCL1, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, MIP-2, 
RANTES, and GM-CSF) using a Milliplex Luminex Kit (Millipore), according to the 
manufacturer’s instructions. 
3.3.8 Flow cytometry 
Cell suspensions (2 x 106 cells/sample) from liver, MLNs, spleen and white adipose 
tissue (WAT) were pre-incubated in FACS buffer with anti-CD16/32 (Fc “blocking” 
antibodies [Abs], clone 93) for 15 min at 4oC, then stained with either fluorescent-
labeled primary Abs or IgG isotype controls for 30 min at 4oC.  The following Abs were 
used: fluorescein isothiocyanate (FITC)-conjugated anti-CD11b (clone M1/70) and anti-
CD25; peridinin cholorophyll-a protein (PerCP)-conjugated CD4; V450-conjugated 
FoxP3; PB-conjugated anti-F4/80 (clone BM8); allophycocyanin (APC)-conjugated anti-
CD11c (N418) and CD8; and APC-Alexa 780-conjugated CD3.  PerCP-conjugated Abs 
were purchased from BD Biosciences, whereas all other Abs were from eBiosciences 
(San Diego, CA).  Cells were gently washed twice in FACS buffer and re-suspended in 
4% paraformaldehyde (Fisher) prior to analysis using a FACSCalibur flow cytometer 
and FACSDiva software (BD Biosciences, San Jose, CA).  A minimum of 50,000 cells 
were analyzed for each sample and a proportion of up to 1% false positive events were 
accepted in the isotype control samples.   
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3.3.9 Statistical analysis 
Data are expressed as means ± SE.  Statistical significance was determined by t-test 
and, where appropriate, analysis of variance (repeated measures or one-way ANOVA; 
Bonferroni's post-hoc test) was performed using the PASW Statistics program (Chicago, 
IL).  Statistical significance was assumed at p ≤ 0.05.   
3.4 RESULTS  
3.4.1 Injection of immature BMDC diminishes body composition gains when 
consuming a high fat diet 
Our lab’s previous data showed that lack of DC completely protects against obesity.  
Additionally, DC increased in number in the liver and white adipose tissue (WAT) when 
animals are placed on a HFD (Stefanovic-Racic, et al., submitted) and our collaborators’ 
work indicates that a single injection of BMDC can prevent the onset of diabetes in a 
NOD mouse [101].  All these findings sparked our interest in determining whether an 
injection of BMDC could prevent the onset of type II diabetes in a diet induced obesity 
model.  We started animals on either a high fat (HFD) or standard chow (SC) diet and 
gave them an injection of 1x106 immature BMDC (iDC), LPS-treated BMDC (LPS-DC), 
or BMDM, once per week for 6 weeks.  Animals on SC showed no differences in weight 
gain (Figure 11A) or adiposity (Figure 11B) between those animals receiving an 
injection of PBS or iDC.  While animals placed on a HFD did not exhibit any differences 
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in weight (Figure 11A), animals receiving an injection of iDC each week showed a 
significant drop in fat mass and %fat compared to control animals (Figure 11B).  
Notably, this is not due solely to the fact that these animals are receiving an injection of 
mononuclear cells because injection with LPS-activated DC or BMDM do not afford the 
same protection (Figure 11C&D). Furthermore, this difference was not attributable to 
changes in caloric intake (Supplemental Figure 1).   
 
 
 
 
 57 
 
Figure 11 - Injection of immature bone marrow-derived dendritic cells alters body 
composition. 
 
Wild-type C57Bl/6 mice were placed on a SCD or HFD and injected once per week with either 
PBS, 1x106 immature BMDC (iDC, Panels A & B), 1x106 LPS treated BMDC (LPS-DC, Panels 
C&D) or 1x106 bone marrow-derived macrophages (BMDM, Panels C&D).  Weight gain was 
assessed, as described in Methods (Panels A & C).  After 5 weeks on the diet, all mice 
underwent dual x-ray absorbitometry (DXA) as described in Methods (Panels B & D).  Results are 
presented as the means±SE for a minimum of six animals in each group.  *p<0.05. 
3.4.2 Exogenous BMDC administration does not change metabolic phenotype 
Given these animals have altered accumulation of fat, we next wanted to test whether 
the metabolic rate or activity of these animals differ from their controls.  Using the 
CLAMS system, we assessed the metabolic rate, as demonstrated by VO2 (Figure 
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12A&B), and activity (Figure 12C&D) and found no differences based on diet or 
injection.   
 
 
Figure 12 - Metabolic analysis using CLAMS (Comprehensive Laboratory Animal 
Monitoring System).   
 
Standard chow (SC) and high fat fed (HFD) wild-type mice injected with either PBS or iDC 
underwent CLAMS analysis, as described in Methods.  Data for VO2 (Panels A and B), and 
ambulatory activity (Panel C & D) are presented.  Results are presented as the means±SE for a 
minimum of seven animals in each group. 
 
3.4.3 Injection of BMDC alters the immunophenotype of WAT 
There is now a seminal body of work implicating the TH1, pro-inflammatory phenotype in 
the development of the metabolic disturbances of obesity.  Given the changes in body 
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composition, we were very interested in discovering how the immunophenotype of these 
animals is altered in response to exogenous administration of BMDC.  Grossly, iDC 
injection causes an influx of immune cells into the WAT of mice, as measured by total 
mononuclear cell (MNC) fraction isolated from the tissues, regardless of diet (Figure 
13A).  There is also a trend towards increased MNC in the liver, but this did not reach 
statistical significance.  More specifically, the numbers of CD4+ T-helper cells (as 
defined by cells expressing CD3 and CD4), regulatory T cells (as defined by 
CD3+CD4+FoxP3+ cells), dendritic cells (the total CD11c+ population) and macrophages 
(CD11b+CD11c- cells) increase in the adipose tissue after iDC injection (Figure 13B).  
These increases were not observed in liver (Supplemental Figure 2) or spleen 
(Supplemental Figure 3).  Importantly, the cytokine profile of the MNC isolated from both 
WAT (Figure 13C and Supplemental Figure 4) and liver (Supplemental Figure 5) 
demonstrated that the cells from these tissues were predominantly TH2 polarized, as 
indicated by a decrease in the ratio of TNFα to IL-4 (TH1 to TH2).   
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Figure 13 - Immunophenotype of iDC injected mice. 
 
White adipose tissue (WAT), mesenteric lymph nodes (MLN) and liver were collected from SC, 
HFD, PBS injected, and iDC injected mice, immune cells were isolated, counted (Panel A) and 
analyzed by FACS (Panel B), as described in Methods.  Additionally, immune cells were kept in 
culture overnight in the presence of 10ng/mL PMA and 500ng/mL ionomycin, and supernatants 
underwent Luminex analysis (Panel C), as described in Methods.  Results are presented as the 
means±SE for a minimum of seven animals in each group. 
3.4.4 Injection of BMDC partially protects against glucose intolerance but not 
steatosis 
While the immunophenotype suggests that iDC injection is protective against the long-
term sequelae of obesity, we were interested in testing specific metabolic parameters of 
the metabolic syndrome: namely insulin resistance, glucose intolerance, and steatosis.  
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Animals on a HFD had worse glucose tolerance than their SC counterparts, as indicated 
by higher GTT curve tracing (Figure 14A) and higher AUC (Figure 14B).  Additionally, 
animals on a HFD that received weekly injections of iDC demonstrated significantly 
improved glucose tolerance as indicated by the lower AUC (Figure 14B). 
 
 
Figure 14 - Glucose tolerance in iDC injected mice.   
Standard chow and high fat fed wild-type mice injected with either PBS or iDC underwent glucose 
tolerance tests (GTT), as described in Methods.  Results are presented as the means±SE for a 
minimum of seven animals in each group.  *p<0.05. 
 
While iDC injection protected against glucose intolerance, the fasting blood 
glucoses (FBG) of these animals remained unchanged to that of controls (Figure 15A).  
Furthermore, liver and plasma TG were not different between the iDC and PBS injected 
groups (Figure 15B&C).   
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Figure 15 - Fasting blood glucose and liver and plasma triglycerides in iDC injected mice.   
Fasting blood glucose (Panel A), and liver and plasma triglycerides (Panels B & C, respectively) 
were assessed in PBS or iDC injected mice, as described in Methods.  Results are presented as 
the means±SE for a minimum of seven animals in each group. 
3.5 DISCUSSION 
The purpose of the current study was to address the potential role of DC in the 
pathogenesis of the metabolic disturbances of obesity.  A number of novel observations 
have been presented.  Namely, C57Bl/6 mice that receive weekly injections of iDC while 
consuming a HFD 1) have predominantly TH2 polarized immune cells within the adipose 
tissue and liver, 2) accumulate lower amounts of fat mass and 3) are protected from 
diet-induced insulin resistance.  We were motivated by previous reports postulating 
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involvement of DC, or cells expressing the classical DC marker CD11c, in the 
development of inflammation and insulin resistance in response to overnutrition.  These 
studies have indirectly noted that triple positive (CD11b+CD11c+F4/80+) cells are 
elevated in the WAT of obese individuals [97,98], have established that these cells are 
responsible for the elevated pro-inflammatory status of obese [98,100] or have directly 
attributed elevations in CD11c+ populations in the WAT and liver to DC (Stefanovic-
Racic, et al., submitted).  Furthermore, Patsouris and colleagues [99] demonstrated that 
removal of all CD11c-expressing cells protects against diet-induced insulin resistance 
and steatosis.   
While it is now established that macrophages are elevated in number and 
activation in obesity [82,84,85], and that the triple positive cells account for much of the 
inflammation present in obese individuals, few studies have specifically studied the 
responses of DC in response to overnutrition.  Utilizing cultured cells, Nguyen et al. 
[100], describe that BMDC, which express CD11c, are more pro-inflammatory than 
BMDM, which do not express CD11c.  Furthermore, they show that BMDC become 
activated after exposure to free fatty acids, which are elevated in the circulation of 
obese individuals [35] and are proposed to exert many effects leading to the sequelae 
of obesity [138].  Our group has recently found that the increases in triple positive cells 
in the WAT of obese mice were due to increases in DC, not macrophages as was 
originally surmised (Stefanovic-Racic, et al., submitted).  We also discovered that DC 
were directly involved in the recruitment of macrophages, to the adipose tissue.  
In the current study, we set out to investigate the role of DC in the development 
of obesity-associated metabolic changes, by administering weekly injections of bone 
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marrow-derived DC to mice eating a HFD.  We were first intrigued by the prospect of 
utilizing DC to alter metabolic fate when referred to studies which show BMDC injection 
protecting against the development of diabetes in non-obese diabetic (NOD) mice, a 
model of type I diabetes mellitus [101].  Furthermore, injection of BMDC has already 
been translated into the clinic for applications in the cancer [139] and transplant [140] 
arenas.  It is this prior knowledge that will help transform any potential therapeutics into 
clinical applications for obesity.  As DC have long been known to play a crucial role in 
the initiation and modulation of innate and adaptive immune responses by recruitment 
and activation of B and T cells [92], we postulated that DCs may be responsible for the 
onset of inflammation and the initiation of a TH1 response in the setting of overnutrition.   
A pro-inflammatory, TH1 polarized immune system is associated with worse 
metabolic outcomes in obesity, such as hepatic steatosis and insulin resistance [141].  
Thus, TH1 polarized T helper cells infiltrate WAT while consuming a HFD [136].  Also, 
M1 polarized macrophages, which promote the skewing towards a TH1 
immunophenotype, are more prevalent in obese adipose tissue [84,85].  Additionally, 
mice with a reduced capacity to recruit these macrophages exhibit lower levels of 
inflammation and are protected from HFD-induced insulin resistance [83,86] and the M2 
polarization of macrophages, which promotes the TH2 skewing of T cells, has been 
associated with improved metabolic outcomes.  Mice that are impaired in their ability to 
develop an M2 response, PPARδ knock out mice, exhibit increased adiposity and 
steatosis while consuming a HFD [90].  This is exemplified by the different susceptibility 
of various strains to diet-induced obesity: Balb/c mice which mount a strong TH2 
response, are resistant to weight gain and steatosis, while C57Bl/6 mice, which mount a 
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strong TH1 response, are highly susceptible to obesity, insulin resistance and steatosis 
when consuming a HFD [142].  Here, we have demonstrated that iDC injection causes 
recruitment of macrophages, T cells and dendritic cells to WAT, regardless of diet 
(Figure 13), and notably, the infiltrating cells were polarized towards a TH2 phenotype.  
While this result is consistent with the current belief that TH2 skewing is beneficial for the 
prevention of the metabolic disturbances of obesity, it brings up an interesting 
contradiction with the work of Patsouris and colleagues [99]: namely that both 
exogenous administration of BMDC and removal of all DC result in improved insulin 
sensitivity.  A recent report from Li et al. [143], however, may shed some light on this 
apparent conundrum.  The authors describe that triple positive cells exhibit phenotypic 
plasticity, i.e. these cells switch from a TH1 polarizing phenotype to a TH2 polarizing 
phenotype after mice are placed on a standard chow diet following consumption of a 
HFD for 20 weeks.  After maintaining the standard chow diet for three weeks, mice have 
decreased weight gain, adiposity and steatosis, as well as improved insulin sensitivity, 
compared to animals remaining on HFD, but still have the triple positive cells.  It, 
therefore, follows logically that the cells themselves do not entirely explain the link 
between inflammation and insulin resistance, but rather the cytokine milieu that those 
cells produce play an important role, as well. Thus, identifying the inflammatory 
landscape may, in fact, be the more important defining criterion for metabolic outcomes.   
One particular observation worthy of note is the improvement of glucose 
tolerance in animals receiving iDC injections.  Other metabolic readouts such as liver 
TG accumulation (i.e. steatosis) and fasting blood glucose were unchanged between 
iDC injected and control animals.  This would indicate that basal levels of 
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gluconeogenesis from the liver are similar in these animals, suggesting that liver insulin 
action is unaltered.  The differences in the GTT AUC may instead reflect differences in 
the action of insulin at the level of the skeletal muscle.  And, although the gold-standard 
test to distinguish liver versus total body insulin resistance would be hyperinsulinemic 
euglycemic clamp studies, we do not believe such experiments are warranted at this 
time. 
In conclusion, we have demonstrated that DC are involved in the determination 
of body composition and insulin resistance that develops in the setting of overnutrition.  
Specifically, the anti-inflammatory TH2 polarized immunophenotype caused by injection 
of immature BMDC is protective against adiposity and insulin resistance.  The 
mechanisms which cause these effects have yet to be determined; however, given that 
DC are known to modulate immune responses by activation and differentiation of T 
cells, studies are currently ongoing to describe the involvement of T cells in the 
protection afforded by iDC. 
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4.0  CHAPTER 4 – THE ROLE OF NKT DELETION ON THE METABOLIC 
DISTURBANCES OF OBESITY2 
4.1 ABSTRACT 
The contribution of natural killer T (NKT) cells to the pathogenesis of metabolic 
abnormalities of obesity is controversial.  While the combined genetic deletion of NKT 
and CD8+ T cells improves glucose tolerance and reduces inflammation, interpretation 
of these data has been complicated by the recent observation that the deletion of CD8+ 
T cells alone reduces obesity-induced inflammation and metabolic deregulation, leaving 
the issue of the metabolic effects of NKT cell depletion unresolved.  To address this 
question, CD1d null mice (CD1d-/-), which lack NKT cells but have a full complement of 
CD8+ T cells, and littermate wild type controls (WT) on a pure C57BL/6J background 
were exposed to a high fat diet, and glucose intolerance, insulin resistance, 
dyslipidemia, inflammation, and obesity were assessed.  Food intake (15.5±4.3 vs 
15.3±1.8 kcal/mouse/day), weight gain (21.8±1.8 vs 22.8±1.4g) and fat mass (18.6±1.9 
vs 19.5±2.1g) were similar in CD1d-/- and WT, respectively.  As would be expected from 
these data, metabolic rate (3.0±0.1 vs 2.9±0.2 ml O2/g/h) and activity (21.6±4.3 vs 
                                                
2 Adapted from 107. Mantell BS, Stefanovic-Racic M, Yang X, Dedousis N, Sipula IJ, et al. (2011) Mice 
Lacking NKT Cells but with a Complete Complement of CD8 T-Cells Are Not Protected against the 
Metabolic Abnormalities of Diet-Induced Obesity. PloS one 6: e19831. 
 68 
18.5±2.6 beam breaks/min) were unchanged by NKT cell depletion.  Furthermore, the 
degree of insulin resistance, glucose intolerance, liver steatosis (12.5±2.2 mg TG/g 
tissue vs 8.4±2.0 mg TG/g tissue), and adipose and liver inflammatory marker 
expression (TNFα, IL-6, IL-10, IFN-γ, MCP-1, MIP1α) induced by high fat feeding in 
CD1d-/- were not different from WT.  We conclude that deletion of NKT cells, in the 
absence of alterations in the CD8+ T cell population, is insufficient to protect against the 
development of the metabolic abnormalities of diet-induced obesity.   
4.2 INTRODUCTION 
Obesity coincides with a state of chronic, low-grade inflammation that has been 
implicated in the pathogenesis of insulin resistance and dyslipidemia.  In particular, it 
has been demonstrated that macrophages, CD8+ T cells and regulatory T cells in 
adipose tissue and liver play a role in mediating the detrimental effects of inflammation 
on metabolism [28,81,82,84,85,144].  However, there continues to be interest in 
determining the potential role for other immune cells in altering metabolism.  In this 
regard, NKT cells are a sub-population of lymphocytes that are proposed to serve as a 
link between the adaptive and innate immune systems [102-104].  NKT cells have 
receptor expression characteristics of NK cells (they are NK1.1+) and T cells (they 
express a T cell receptor (TCR)).  Notably, the NKT TCR, rather then being activated by 
peptide antigens, is activated by glycolipid antigens through the MHC class I-like 
molecule, CD1d [102-104], while an alternative activation pathway is dependent on 
cytokine signaling from activated dendritic cells [103].  Irrespective of the method, 
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activation of NKT cells results in rapid cytokine production (within hours), which may be 
of mixed, TH1 or TH2 dominance depending on the microenvironment to which the NKT 
cells are exposed and/or different functional subsets of NKT cells [104]. 
The potential role of NKT cells in altering metabolism has received attention, but 
the data are inconclusive and somewhat contradictory.  Of relevance to the current 
study are the observations that diet-induced obese mice [105,145] and ob/ob mice [108] 
have a larger proportion of TH1 polarized liver NKT cells than non-obese mice [105], 
and that administration of the NKT activator α-Galactosylceramide to DIO mice 
exacerbates glucose intolerance and adipose tissue inflammation [106], suggesting that 
NKT may play a pathogenic role in the metabolic abnormalities associated with these 
models.  Conversely, obesity reduces overall NKT cell numbers in liver [105,108,109], 
while an agonist of NKT cells, glucocerebroside [146], or adoptive transfer of NKT cells 
[110] improves liver steatosis and glucose tolerance in ob/ob mice, suggesting a 
protective effect of NKT cells.  Clearly, an approach that would clarify some of these 
issues would be to ablate NKT cells and address the consequences of this manipulation 
on the development of metabolic deregulation in obesity.  Indeed, a recent study [106] 
demonstrated that mice lacking NKT cells have reduced adipose tissue inflammation 
and improved glucose tolerance compared to wild-type mice when exposed to a high fat 
diet.  However, the animals used in this study were also depleted of CD8+ T cells, a 
vitally important caveat, since a recent study demonstrates a role for CD8+ T cells in 
driving obesity-related inflammation and deregulated glucose homeostasis [79].  Thus, 
the metabolic and inflammatory effects of NKT cell deletion alone remain unknown.  The 
current study was undertaken to address this issue.  To accomplish this goal, mice 
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lacking CD1d were used.  These animals are depleted of NKT cells but maintain a 
normal complement of CD8+ T cells [147,148], making it possible to demarcate the 
effects of NKT cell deletion alone from the effects of combined NKT/CD8+ T cell 
deletion. 
4.3 MATERIALS AND METHODS 
4.3.1 Animal care and maintenance 
CD1d-/- mice on a Balb/c background (C.129S2-Cd1tm1Gru/J) were obtained from 
Jackson Laboratories.  Homozygous mutant mice are deficient in both the Cd1d1 and 
Cd1d2 genes and as a result lack the natural killer T subset[147,148].  These mice were 
bred with C57Bl/6 mice to obtain N1F1 heterozygotes, which were subsequently 
backcrossed to pure C57Bl/6 mice.  The gender of the mice in the backcross was 
alternated with each generation.  CD1d heterozygotes of at least the N7 generation 
(>99% Bl/6 background) were mated to obtain CD1d-/- and wild type littermate controls.  
Prior to experiments, mice were maintained on a constant 12-h light:12-h dark cycle 
with free access to water and ad libitum fed with a standard chow diet.  All procedures 
were approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Pittsburgh, and were in accordance with the National Research Council's 
Guide for the Care and Use of Laboratory Animals. 
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4.3.2 Experimental design 
CD1d-/- (n=9) and wild type littermate control mice (n=11) were fed ad libitum with a 
standard chow (SC) or high fat (HF) diet (44% calories from fat – 19% Lard, 1% Corn 
Oil) from Harlan Teklad for 26 weeks.  Mice and food were weighed weekly for the 
course of the experiment.  During this period, mice underwent an analysis of insulin 
sensitivity using glucose tolerance and insulin tolerance tests, metabolic rate using the 
CLAMS (Comprehensive Laboratory Animal Monitoring System, OH), and body 
composition using a Lunar PIXImus densitometer (Lunar, Madison, WI).  Whole-body 
scans, with exclusion of the head, were analyzed for fat and lean masses using the 
manufacturer’s software.  At the end of this period, blood and tissues were isolated, 
flash frozen and stored at –80°C until analysis. 
4.3.3 Glucose tolerance tests (GTT), insulin tolerance tests (ITT), and pyruvate 
tolerance tests (PTT) 
For the GTT, 6-hour fasted mice were injected i.p. with 1.5 g/kg glucose.  Blood was 
sampled from the tail vein every 15 minutes for 2 hours post-injection and glucose was 
measured using an Ascensia Elite glucometer (Bayer, Mishawaka, IN).  For the ITT, 
non-fasted animals were injected i.p. with 1 unit/kg of human recombinant insulin 
(Humulin R, Lilly, Cincinnati, MO).  Blood was sampled from the tail vein every 15 
minutes for 2 hours post-injection and glucose was measured using an Ascensia Elite 
glucometer.  For the PTT, 6-hour fasted mice were injected i.p. with 2 g/kg Sodium 
Pyruvate.  Blood was sampled from the tail vein every 15 minutes for 2 hours post-
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injection and glucose was measured using an Ascensia Elite glucometer (Bayer, 
Mishawaka, IN). 
4.3.4 Tissue collection and generation of single mononuclear cell suspensions 
for flow cytometric analysis 
At the end of the 26 week diet, blood was collected by cardiac puncture, then 10mL 
PBS was perfused through the liver from the proximal IVC, one of the smaller lobes of 
the liver was then removed and flash frozen for triglyceride measurements.  
Subsequently, 5mL of a 1mg/mL solution of collagenase (type IV; Sigma C-5138, St. 
Louis, MO) was perfused to release hepatocytes and non-parenchymal cells from the 
surrounding connective tissue.  Spleen and epididymal and renal fat pads were 
collected as well.  Livers were agitated to release cells, then incubated at 37°C 5% CO2 
for 30 min.  Resulting digest was passed over a 70um cell strainer, hepatocytes were 
removed with one 45 x g centrifugation, and mononuclear cells in the supernatants were 
pelleted, then isolated on an 8% Histodenz gradient.  Fat pads were combined and 
digested in a 1mg/mL collagenase solution, then passed over a 100um cell strainer.  
Red blood cells were lysed using Red Blood Cell Lysing Buffer (Sigma R7757) twice. 
4.3.5 Flow cytometry 
Cell surface staining was performed in PBS containing 2% FBS with the following 
antibodies: anti-CD3-FITC, anti-CD3-PB, anti-CD69-PE, anti-CD8-PerCP, and anti-
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NK1.1-PE/Cy7.  Stained cells were analyzed on an LSR II (BD Biosciences) using 
FACSDiva software (BD Biosciences).   
4.3.6 Tissue and plasma measurements 
Liver triglycerides were determined as previously described [48,130].  Plasma insulin 
levels were measured using a commercial kit (by ELISA; ALPCO, Salem, NH) according 
to the protocol provided by the manufacturer. 
4.3.7 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
For analysis of gene expression, total RNA was isolated from liver or adipose tissue 
using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions.  RT-PCR was carried out using gene specific primers, SYBR green master 
mix (Bio-Rad, Hercules, CA) and an Applied Biosystems Prism 7300 Real-Time PCR 
System, as previously described [63].  Fold change in mRNA expression was 
determined using the ΔΔcT method, with all genes normalized to β−actin. 
4.3.8 Statistical analysis 
Data are expressed as means ± SE.  Statistical significance was determined by t-test 
and, where appropriate, analysis of variance (repeated measures or one-way ANOVA; 
Bonferroni's post-hoc test) was performed using the PASW Statistics program (Chicago, 
IL).  Statistical significance was assumed at p < 0.05. 
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4.4 RESULTS 
4.4.1 Early and reversible decrease in liver NKT cells in response to a high fat 
diet 
Previous studies have reported decreases in liver NKT cells in response to a high fat 
diet.  We first sought to confirm and extend these observations, and to assess the 
effects of diet in other relevant tissues of C57BL/6J mice.  In agreement with previous 
studies [105,108,109], there was a selective decrease in the NKT cell population and 
the NKT activation marker, CD69 in the liver (Figure 16A&B) after exposure to a high fat 
diet.  Conversely, the NKT cell population was enriched in adipose tissue (Figure 16A).  
NKT populations were not altered in the spleen or mesenteric lymph nodes (MLN).  To 
assess the time-course and reversibility of high fat diet-induced alterations in NKT cells, 
mice were placed on a high fat diet for 3 weeks, and then a proportion of these mice 
were placed back on a standard chow diet for a further 3 weeks.  In response to a 3-
week high fat diet, the proportion of NKT cells was reduced to a similar extent as that 
observed with a prolonged diet.  Furthermore, reversion to a standard chow diet for 3 
weeks was sufficient to reverse the alterations in NKT cells (Figure 16C).  Additionally, 
there was no change in NKT cell numbers in the spleen at 3 weeks of HFD or when the 
animals were subsequently placed on a standard chow diet for a further 3 weeks 
(Figure 16D). 
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Figure 16 - Alterations in tissue NKT cell composition in the setting of high fat feeding. 
Wild-type C57Bl/6 mice were placed on a SCD or HFD for 26 weeks (Panels A and B), 3-weeks 
(Panel C and D), or 3 weeks followed by a 3-week standard chow diet (Panel C and D).  White 
adipose tissue (WAT), spleen, mesenteric lymph nodes (MLN) and liver were collected from lean 
and obese mice, immune cells were isolated and underwent FACS, as described in Methods.  
Results are presented as the means±SE for a minimum of five animals in each group.  *p<0.05. 
 
4.4.2 NKT depletion does not alter weight gain, food intake, adiposity, or energy 
expenditure 
The CD1d-/- null mouse lacks NKT cells but has a normal complement of CD8+ T cells 
([147,148] and Figure 17E).  CD1d-/- mice and littermate wild-type controls (WT), on a 
pure C57BL/6J background, were exposed to a high fat diet, and a number of metabolic 
variables were assessed.  Weight gain, caloric intake, and body composition were 
unaffected by NKT cell deletion (Figure 17A-D).  Furthermore, indirect calorimetry 
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demonstrated that metabolic rate and activity were similar in CD1d-/- and WT mice 
(Figure 18A-C), as would be expected given the lack of an effect on NKT depletion on 
body composition and caloric intake.   
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Figure 17 - Weight gain and body composition of wild type (WT) and CD1d null (KO) 
littermate mice on a high fat diet. 
 
Weight gain and caloric intake were assessed in high fat fed wild-type and CD1d knock out mice, 
as described in Methods (Panels A-C).  All mice underwent dual x-ray absorbitometry (DXA) as 
described in Methods (Panel D).  CD8+ T cells were assessed by FACS (Panel E).  Results are 
presented as the means±SE for a minimum of five animals in each group. 
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Figure 18 - Metabolic analysis using CLAMS (Comprehensive Laboratory Animal 
Monitoring System).   
 
High fat fed wild-type (WT) and CD1d null (KO) mice underwent CLAMS analysis as described in 
Methods.  Data for VO2 (Panels A and B), and ambulatory activity (Panel C) are presented.  
Results are presented as the means±SE for four animals in each group.   
4.4.3 Insulin sensitivity and glucose tolerance are unaffected by NKT cell 
deletion 
We next assessed the effects of NKT deletion on obesity-induced insulin resistance 
(Figure 19), using insulin (ITT) and glucose tolerance tests (GTT).  As Figure 19, Panels 
A&B show, the GTT and ITT demonstrate that the degree of insulin resistance in obese 
CD1d-/- mice was similar to obese WT mice.  This is also indicated by the area under 
the curve for the GTT and ITT (Figure 19C and 19D, respectively).  Fasting blood 
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glucose concentrations were similar between WT and CD1d-/- mice, as were the fasting 
insulin concentrations and HOMA values (Figure 20A-C).  Liver triglyceride levels were 
also measured and again, no difference between the groups was observed (Figure 
20D).  Additionally, Pyruvate Tolerance Test (Figure 20E) indicated no difference 
between the two groups. 
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Figure 19 - Glucose and insulin tolerance in wild-type and CD1d-null mice. 
 
High fat fed wild-type (WT) and CD1d null (KO) mice underwent glucose tolerance tests (GTT) as 
described in Methods.  After 1 week for recovery, all mice underwent insulin tolerance tests (ITT) 
as described in Methods.  Results are presented as the means±SE for a minimum of five animals 
in each group. 
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Figure 20 - HOMA, Hepatic glucose output and liver triglycerides in wild-type and CD1d 
null mice. 
 
Fasting blood glucose (Panel A) and plasma insulin (Panel B) concentrations, Pyruvate Tolerance 
Test (Panel E) and liver triglycerides (Panel D) were assessed in WT and KO mice as described 
in Methods.  Results are presented as the means±SE for a minimum of five animals in each 
group. 
4.4.4 Deletion of NKT cells does not alter expression of inflammatory markers 
The inflammatory response in obesity is well described and involves increased 
expression of TH1 cytokines and macrophage infiltration/activation into adipose tissue 
and liver [15,82,84,85,91].  A previous study [106] demonstrated that the combined 
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deletion of CD8+ T cells and NKT cells reduced adipose tissue inflammation in obesity.  
However, the effects of NKT deletion alone are unknown.  Thus, we next assessed the 
effects of NKT deletion on the expression of inflammatory markers in WAT and liver of 
obese CD1d-/- and WT mice.  As Figure 21 shows, qRT-PCR analysis of TNFα, IL-6, IL-
10, IFN-γ, MCP-1 and MIP1α demonstrated that expression of these genes was similar 
in CD1d-/- and WT animals.  These data, taken with the data presented above 
demonstrate that deletion of NKT cells alone is not sufficient to alter the inflammatory 
status of obesity.   
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Figure 21 - Inflammatory marker expression in adipose tissue and liver of wild-type and 
CD1d null mice. 
 
qRT-PCR was used to assess the expression of indicated genes in liver and adipose tissue from 
high fat fed wild-type (WT) and CD1d null (KO) mice.  Results are presented as ΔΔCt (KO/WT) 
±SE for a minimum of five animals in each group. 
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4.5 DISCUSSION 
The major goal of this study was to address the contribution of NKT cells to the 
development of the metabolic abnormalities of obesity, motivated by previous reports 
that have suggested metabolic and inflammatory effects of altered NKT activity.  These 
studies have either indirectly inferred roles for NKT cells [105,108,109], altered the 
activity/numbers of NKT cells in pre-existing obesity models [106,110,145,146,149], or 
have deleted other cell types i.e. CD8+ T cells, in addition to NKT cells [106], that have 
been implicated in mediating increased inflammation and metabolic deregulation in 
obesity.  Importantly, no previous studies have been undertaken in models with a 
specific deletion of NKT cells.   
To investigate the role of NKT cells in the development of obesity-related 
metabolic disturbances in the absence of alterations in CD8+ T cells, we utilized the 
CD1d knockout mouse line, which lacks NKT cells, but has a full complement of CD8+ T 
cells, as opposed to the β2-microglobulin knockout mouse used in a previous study, 
which lacks both NKT and CD8+ T cells [106].  Furthermore, and again unlike the study 
of Ohmura et al. [106], the current study controlled for the genetic background of the 
mice by utilizing wild-type littermates of the C57Bl/6J CD1-/- mice.  The Ohmura study 
[106] demonstrated that deletion of both NKT and CD8+ T cells results in an 
improvement in the glucose intolerance and inflammation resulting from exposure of the 
animals to a high fat diet.  The authors conclude that it is unlikely that CD8+ T cells 
contribute to this phenotype.  However, given the more recent study of Nishimura et al. 
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[79], which demonstrates a role for CD8+ T cells in mediating the inflammation and 
metabolic abnormalities of obesity, and the data obtained in the current study, a more 
likely explanation is that much, if not all, of the improvements in metabolic function and 
inflammation observed in the β2-microglobulin null mouse are due to the absence of 
CD8+ T cells.   
While we did not expect a lack of NKT cells to effect gross body composition, we 
next sought to discover any changes in metabolic phenotype of these animals.  We 
used a Comprehensive Laboratory Animal Monitoring System (CLAMS) to 
simultaneously measure energy expenditure, caloric intake and activity levels in four 
WT and four KO mice.  We found no difference in energy expenditure, activity, 
respiratory exchange ratio, or caloric intake between the two groups of animals.  As a 
point of interest, we looked at these data in different ways, including normalizing for total 
body weight and lean body mass.  When incorporating to body weight, differences 
between the two groups become statistically significant, however, as Butler and Kozak 
suggest [150], this can be misleading due to small (<10%) differences in the weights of 
the animals that were run in the CLAMS.  We posited that the most appropriate way to 
present the VO2 and heat data would be as per kg animal, especially considering that 
the body composition of the two groups of animals was not statistically different. 
A number of studies have addressed the effects of obesity on NKT cell 
populations and activity [105,109,145] and the effects of interventions that alter NKT cell 
activity or number [106,110,145,146,149] on the metabolic abnormalities of obesity.  By 
putting the current observations in the context of these studies, it is possible to 
conjecture on the various and somewhat contradictory conclusions reached in these 
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reports.  The issue of the contribution of CD8+ T cells to the metabolic phenotype of β2-
microglobulin null mouse has been dealt with above.  Turning to the effects of obesity 
on NKT cell populations and activity, it is now well established that obesity reduces liver 
NKT cell numbers [105,108,109], and that the remaining NKT cells are TH1 polarized 
[109,149].  However, although these studies are suggestive and are useful for 
hypothesis generation, by themselves they do not demonstrate a causative role for NKT 
cells in development of the metabolic or inflammatory abnormalities of obesity.  More 
direct studies have attempted to manipulate the activity or number of NKT cells in vivo.  
One approach has been to administer glycolipids, which are NKT cell agonists, to obese 
animals and determine the metabolic consequences of this intervention.  Thus, Ohmura 
et al. report that administration of α-Galactosylceramide (αGC), which is reported to 
expand the iNKT population [106], to DIO or ob/ob mice exacerbates adipose tissue 
inflammation (DIO and ob/ob) and glucose intolerance (DIO).  However, while the 
effects of αGC on inflammatory status in this study are substantial, the effects on 
glucose tolerance are small, although they are statistically significant.  Administration of 
glucocerebroside (β-Glucosylceramide) is reported to improve liver steatosis and 
glucose intolerance in ob/ob mice[146], although the effects of this glycolipid on NKT 
cell activity is unclear.  Unfortunately, NKT cell activity was not assessed in this study.  
However, it is possible that these two glycolipids have differential effects on NKT cell 
activity or expand different subsets of NKT cells, although these issues have not been 
addressed.  Finally, adoptive transfer of NKT cells improves liver steatosis and glucose 
tolerance in ob/ob mice [110].  Unfortunately, polarization of the transferred cells was 
not assessed in this study, so again we are left to conjecture that perhaps the beneficial 
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effects are the result of the specific NKT cell subset used in this study and/or their 
polarization.  Putting these studies in the context of the current study, we can say that 
ablation of NKT cells does not appear to protect against or contribute to the metabolic 
abnormalities of obesity.  However, interventions that alter specific NKT populations or 
their activity in a pre-existing state of obesity appear to result in alterations in 
inflammatory status and metabolic function, the direction of which may be dependent on 
the specific NKT population targeted or the effects of the intervention on NKT 
polarization. 
Two observations worthy of note are the rapidity with which nutrient composition-
induced alterations in the liver NKT cell population occurs, and the different responses 
of the liver and adipose tissue NKT populations in obesity.  We demonstrated that as 
little as 3 weeks of high fat diet exposure was sufficient to induce alterations in the liver 
NKT population.  Furthermore, these changes were rapidly reversed when mice were 
returned to a low fat chow diet.  Together, these data indicate that the liver 
microenvironment is very sensitive to altered nutrient states, and as for longer term 
diets, these changes correlate with hepatic metabolic and inflammatory alterations, 
since it is well-established that liver steatosis and insulin resistance and inflammation 
are present in rodent models within a 1-3 week exposure to a high fat diet.  We 
analyzed multiple tissues of obese C57Bl/6 mice to extend previous observations of 
decreases in liver NKT cells.  As others have shown, we observed a decrease in the 
percentage of NKT cells in the liver [105,149], however we also found an increase in 
NKT cells in the white adipose tissue.  As opposed to Miyazaki et al. [145], but similar to 
Li et al.[105], we did not see a difference in the NKT populations in the spleen.  In 
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conclusion, the current study emphasizes the complex relationship between NKT cells 
and metabolism and suggests that the simple removal of NKT cells does not influence 
metabolic regulation in obesity. 
 
 86 
5.0  SUMMARY AND CONCLUSIONS 
5.1 KNOWLEDGE GAPS IN THE FIELD 
The seminal papers by Xu et al. and Weisberg et al. in 2003 [84,85], inspired significant 
amounts of research investigating the role of the immune system in the development of 
the metabolic disturbances of obesity.  Much of this subsequent research has centered 
on responses of macrophages in the white adipose tissue of obese individuals.   The 
work presented throughout this dissertation has sought to define additional aspects of 
how our immune system responds to and affects nutrient metabolism in the setting of 
overnutrition. 
I have proposed that in response to elevations in circulating free fatty acids, 
parenchymal cells of the liver and adipose tissue (i.e. hepatocytes and adipocytes, 
respectively) will increase expression of factors that recruit macrophages and DC, 
causing immune cell infiltration into these tissues, as illustrated in Figure 2.  I have 
shown evidence that macrophages are, then, capable of producing PGE2, which, in 
turn, decreases hepatocyte lipid oxidation rates.  Furthermore, I have described a 
situation in which DC induce a TH2 phenotype in liver and adipose tissue, thus 
protecting against diet-induced insulin resistance. While it is now established that 
immune cells are linked to obesity, we still need to understand the mechanism of these 
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changes to drive the rational design of therapeutics and appropriate prevention of 
disease, in the clinical arenas, as well as advancement of scientific knowledge and to 
generate new questions, in the basic science arenas.  Prior to the work described in the 
preceding chapters, much preliminary work had been done ascribing a role for 
inflammation and the immune system in the determination of the metabolic disturbances 
of obesity; however, a number of key questions remain.   
As described earlier, leading up to the work performed in completion of this 
dissertation, we have seen many associative studies and glimpses into the importance 
of the immune system in determining metabolism under the challenge of overnutrition.  
Thus, migration of macrophages into WAT is necessary for diet-induced insulin 
resistance and steatosis [83,86], and the pro-inflammatory M1 and TH1 phenotypes of 
macrophages and T cells, respectively, are detrimental to maintaining insulin 
responsiveness in comparably healthy individuals [141].  Additionally, we have seen the 
importance of the NF-κB pathway and the involvement of the pro-inflammatory cytokine 
TNFα [28,141].  Furthermore, there was controversy over the role of NKT cells in 
determining the metabolic changes during overnutrition [107] and there were only hints 
that DCs were involved at all [99,100].   
This preliminary work in the field of immune modulation of metabolism was 
fundamental in establishing a previously unrecognized method of maintaining nutrient 
homeostasis, but, at the same time, raised many questions.  From these studies, we 
understand that macrophages play a major role in determining insulin resistance and 
steatosis in the setting of obesity; however, the mechanism by which macrophages 
cause these changes was unknown.  Furthermore, there have been no definitive studies 
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to date determining whether the immune cell infiltration and inflammation occurs prior to 
the development of metabolic abnormalities, or vice versa.  As early as two days on a 
HFD, macrophage infiltration can be measured in the liver in addition to steatosis [151], 
while another group has demonstrated that the same occurs in the adipose tissue as 
early as three days after starting a HFD [152].  Also, the controversy over NKT cell 
involvement and the lack of definitive studies investigating the role of DC begs the 
question of whether, or not, each of these cell types plays a part in determining the 
metabolic disturbances of obesity.  The results presented in this dissertation have 
provided some insight into these questions, which have implications for the field at 
large. 
5.2 IMPLICATIONS OF THE WORK DESCRIBED 
The first obvious implication of the work described is the development of a new 
technology: the use of mouse hepatocyte/KC co-cultures for metabolic studies.  We are 
one of the first groups to utilize mouse hepatocytes in co-culture with KC for studies of 
lipid metabolism.  Prior to this innovation, only rat hepatocytes and KC had been used 
for co-culture metabolic studies [91].  This approach has the limitation of only 
investigating cell responses in their normal/wild type state, while the use of mouse cells 
introduces a multitude of potential manipulations.  The flexibility of the mouse system is 
demonstrated in Figure 3B, where TLR4 knock out KC are utilized in combination with 
wild type hepatocytes to show that TLR4 is required in the KC to decrease hepatocyte 
palmitate oxidation.  Interestingly, although TLR4 is required (Figure 3B), and palmitate 
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and LPS both activate TLR4 [37], the cells seem to respond differently to the two 
ligands (Figure 3A).  This could represent differences in the signaling of each of these 
molecules, either upstream or downstream of TLR4, or may suggest a role of accessory 
receptors in mediating the effects. 
This is not to say, however, that the mouse system is without limitations itself.  
Indeed, as is the case with any in vitro model system, the mouse co-culture system is a 
simplification of the physiological case that actually occurs in the liver.  Thus, many 
more than just two cell types interact within the liver and they do not only interact by 
passing soluble factors to each other.  Signals that require direct cell-to-cell contact may 
also alter the metabolic status of an animal.  With that said, though, the mouse co-
culture system has helped to define one potential mechanism of macrophage-mediated 
alterations in metabolism. 
The experiments performed in Chapter 2 implicate PGE2 in paracrine crosstalk 
between hepatocytes and KC resulting in decreased lipid breakdown.  Our receptor 
expression data (Figure 6) point towards an involvement of EP1 or EP4 in mediating the 
effects of PGE2 on hepatocyte metabolism.  Interestingly, all four subtypes of the PGE2 
receptor are G-protein coupled receptors, but to different G-proteins.  Specifically, EP1 
is linked to Gq, thus it acts to increase the intracellular concentration of calcium in a cell 
via phospholipase C and calcium release from the endoplasmic reticulum.  EP4 is linked 
to Gs, and thus acts to increase cAMP production via activation of adenylate cyclase 
(AC).  Given that PGE2 decreases palmitate oxidation (Figure 5), we thought that it 
would be unlikely that cAMP was involved, because glucagon, a hormone that activates 
AC in the fasted state (opposite to insulin), acts to increase β-oxidation.  This, however, 
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raises the question of whether all receptors linked to Gq can inhibit palmitate oxidation in 
hepatocytes.  In this regard, carbachol, a pan-muscarinic agonist, activates the M1, M3 
and M5 receptors, which are all linked to Gq, and subsequently raises intracellular 
calcium concentrations.  Even though carbachol is a somewhat non-specific mediator 
used to raise calcium concentrations, the result that it can recapitulate the PGE2 effect 
of lowering oxidation rates provides added confidence that PGE2 is exerting its effects 
through EP1.  A more definitive test for the involvement of EP1 would be to use an EP1 
inhibitor such as SC-51322.  We would expect to block the KC-mediated decreases in 
hepatocyte palmitate oxidation with the inclusion of SC-51322.  Furthermore, if PGE2 is 
exerting these effects via elevation of calcium within the cell, we would expect to block 
this effect with the addition of a calcium channel blocker, such as verapamil.  Another 
way we aimed to demonstrate the involvement of PGE2 in the effects of KC on 
hepatocyte metabolism was by preventing its production (Figure 7). 
Perhaps the most convincing piece of evidence that PGE2 is involved in 
metabolic crosstalk between hepatocytes and KC is that indomethacin, a generic COX-
1/COX-2 inhibitor, completely blocks KC-induced decreases in hepatocyte palmitate 
oxidation.  Unfortunately, indomethacin is impractical for use in human studies because 
of the GI side effects, but the development of small molecules capable of more specific 
targeting may circumvent this issue.  We also attempted to utilize KC which were 
defective in producing PGE2 in our co-culture system.  The Ptges2 gene product, 
microsomal PGE2 synthase (mPGES)-2, is the constitutively active PGE2 synthase, 
however, as demonstrated in Figure 7C, Ptges2 knock out KC still produce significant 
amounts of PGE2 in response to palmitate.  A more appropriate model may be to use 
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KC from mPGES-1 knock out mice.  mPGES-1, as opposed to mPGES-2, is an 
inducible form of PGE2 synthase, which has been shown to become activated in 
peritoneal macrophages in response to LPS [143].  If we find that mPGES-1 knock out 
KC still produce PGE2 in response to palmitate, it would constitute yet another 
difference between LPS’s and palmitate’s action on KC.  Alternatively, if mPGES-1 
knock out KC do not produce PGE2, we would be able to test more specifically whether 
PGE2 from the KC is acting on hepatocytes to decrease palmitate oxidation.  
Furthermore, another strategy we could use to block the effects of PGE2 would be to 
use hepatocytes from mice that lack the EP1 receptor.  To further investigate the effects 
of PGE2, we recently started testing other endpoints of lipid metabolism beyond 
palmitate oxidation: namely, palmitate esterification and the accumulation of 
triglycerides (TG) with hepatocytes.   
Esterification of lipids and TG accumulation are both anabolic processes, i.e. 
building up components of lipid.  Under normal circumstances, these processes oppose 
β-oxidation.  It was, therefore, somewhat perplexing when we found that esterification 
also decreased when adding KC to the hepatocytes (Figure 9).  We did see trends 
towards increasing TG accumulation with both the addition of KC and the addition of 
PGE2, however this represents an n=2, so repetition will be required to confirm this 
result.  In light of decreased oxidation, the most likely mechanism for triglyceride buildup 
is an increase in lipid esterification.  However, cells can still accumulate TG in the 
absence of an increase in esterification.  For this to occur, another process, such as 
lipid trafficking, would need to be altered in addition to the routine mechanism of 
anabolic and catabolic activities on lipids.  For example, if VLDL secretion was inhibited 
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by the addition of KC or PGE2, as demonstrated by Björnsson et al. [125], then TG 
could accumulate within the hepatocyte, even in the absence of a concordant increase 
in palmitate esterification.   There are a number of enzymes involved in the coordination 
of these processes.  We have begun to investigate one such enzyme: acetyl-CoA 
carboxylase (ACC). 
ACC is a key lipogenic enzyme which becomes activated in the fed state, a time 
when we want to store fats.  It catalyzes the formation of malonyl-CoA, which inhibits 
the opposing process of lipid breakdown (β-oxidation).  ACC is activated by 
dephosphorylation; therefore, if ACC activation is responsible for the decrease in β-
oxidation, we would expect that ACC phosphorylation decreases when we treat our 
hepatocytes with PGE2.  At this point in time, we only have one experiment completed, 
but there is a trend towards decreasing ACC phosphorylation in response to PGE2 
treatment when palmitate is present (Figure 8 B&C).  This result may be indicating a 
mechanism by which PGE2 exerts its effects; however, repetition is needed to confirm 
these results, and additional co-culture experiments are required to determine if this is 
also occurring in response to KC.  Furthermore, ACC activation in response to PGE2 
treatment would predict an increase in esterification in addition to the increase in TG 
accumulation and decrease in oxidation.  Whether or not ACC is responsible for PGE2’s 
effects on lipid metabolism, the increase in TG accumulation and decrease in oxidation 
are changes consistent with the development of steatosis.  A wholesale removal of 
PGE2, however, was bound to prove more complicated than simply protecting against 
the development of steatosis, since many different functions have been attributed to 
PGE2 within the body. 
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Intriguingly, PGE2 has been shown to have multiple, and apparently conflicting 
functions on a given target tissue [116].  PGE2 inhibits TH1 responses [153]; therefore, a 
whole body knock out of Ptges2 may benefit the hepatocyte (since oxidation levels will 
remain elevated and TG accumulation will remain low), but may, in fact, worsen the 
immunological phenotype.  Thus, these animals had the potential to exhibit either an 
improved or worse metabolic phenotype than their WT counterparts when placed on a 
HFD.  We discovered that the Ptges2 KO animals exhibited greater fat mass gain, but 
no worsening of insulin resistance or steatosis beyond the level of the WT animals 
(Figure 10).  Given the substantially elevated fat mass, we would expect steatosis to 
have been worsened in these animals; however, liver triglycerides were unchanged 
between the WT and KO groups. This could either be an indication that the lower levels 
of PGE2 were actually protective against the development of steatosis, or the steatosis 
caused by a ten week HFD could be masking the effects of PGE2 removal.  Another 
possibility speaks to one of the limitations of this system described earlier; namely that 
our in vitro system is an isolated system, which only investigates interactions between 
two cell types and any soluble factors that are passed between the two.  The complexity 
of the in vivo setting, which involves many cell types and both soluble signals and direct 
cell-contact signals, may be another explanation for the lack of difference between the 
two groups.  It is also possible that the multitude of signals in vivo results in normalized 
oxidation rates in the liver of KO animals.  Unfortunately, these studies did not assess 
oxidation rates in the livers of the WT and KO animals, so we are left to conjecture the 
cause of this result.  Additionally, it would be an extraordinary stretch to conclude that 
PGE2 produced by KC is the only mechanism by which immune cells alter metabolism.  
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Indeed, the experiments performed in Chapter 3 would indicate that not only KC are 
involved in metabolic regulation, but DC are as well. 
Throughout Chapter 3, I elucidated a role for DC in the determination of body 
composition and insulin resistance when mice are challenged with a HFD; however, the 
mechanism(s) for these effects remain unknown.  The injection of iDC could result in 
changes within liver and/or WAT and/or skeletal muscle to alter these processes.  
Furthermore, the injected iDC could be acting directly on these target tissues, could be 
activating other immune cell types which act on target tissues or, even, endogenous DC 
could be processing the injected iDC, presenting antigen from the iDC, and either acting 
on the target tissues or activating other cells.  Regardless of mechanism, the data 
presented offer a significant amount of new information.  In particular, we can now 
conclude that some factor specific to iDC, or at least not present in LPS-DC or BMDM, 
is protective against the accumulation of fat tissue in the setting of consuming a HFD 
(Figure 11).  If the injected cells are directly causing the effect (or indirectly via altering 
the activity of other cell types), this could represent a functional difference between the 
various cell types tested, e.g. antigen processing and presentation, expression of co-
stimulatory molecules or cytokine production.  Alternatively, if endogenous DCs are 
processing the injected DC, an antigen specific to iDC could potentially be causing this 
result.  Again, however, irrespective of the mechanism, injection of iDC alters the 
immunophenotype in the WAT and liver of these animals (Figure 13). 
Our data, indicating that injection of iDC promotes TH2 polarization, parallel the 
sentiments of the field that a TH1 skewed immunophenotype is detrimental to the 
sequelae of obesity, while a TH2 skewed immunophenotype may be protective.  
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Importantly, injection of iDC overrides the influence of obesity, which, by itself, causes 
infiltration to the WAT of a predominantly TH1 skewed phenotype.  However, it is 
currently unclear why injection of iDC would predominantly cause infiltration of immune 
cells into WAT.  There is no obvious anatomical or physiological reason that cells 
injected intraperitoneally (i.p.) ought to cause mononuclear cell infiltration into 
epididymal and peri-renal fat pads, and our attempts at tracking experiments were 
inconclusive (data not shown).  Importantly, we cannot explicitly rule out the possibility 
that the increase in DC numbers observed within the adipose tissue was not a direct 
measurement of the injected cells.  The mice were sacrificed one week after the final 
injection, by which time other studies have suggested the injected cells are 
undetectable, but a number of important caveats prevent direct correlation to the 
present study.  The present study injected DCs i.p., whereas many other studies inject 
BMDC subcutaneously or intravenously [154].  Additionally, the majority of studies 
which track i.p. injected cells do not report findings past 48 hours-post-injection.  
Indeed, Shinomiya et al. demonstrate that BMDC are detectable in the spleen, liver, gut, 
pancreas and kidney 24 hours after i.p. injection [155], and Eggert and colleagues use 
the same method to determine these cells are not present in these tissues after 48 
hours [156].  Notably, they show that most of the injected cells remain at the site of 
injection, but again, no information on cell migration after 48 hours was presented.  
Creusot et al. [157] measured DC migration to a multitude of tissues at a number of 
different time points and demonstrate that BMDC injected i.p. mostly disappear from the 
tissues of recipient mice by day 5-6, although they did not test C57Bl/6 animals and 
there were notable differences between the two strains they did test (NOD and FVB), 
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indicating these results may not hold true for C57Bl/6 mice. Intriguingly, Creusot and 
colleagues also demonstrate that 3 days after i.p. injection, BMDC migrate to the 
omentum, which is predominantly composed of adipose tissue.  While, migration to 
epididymal or peri-renal adipose tissue was not reported in any of the above studies, 
these latter findings suggest that i.p. injection of iDC may track to fat depots.  If our iDC 
injections home to the epididymal and peri-renal fat pads, it is quite possible they are 
directly responsible for recruiting the T cells, DCs and macrophages presented in Figure 
13.  Interestingly, not only was immunophenotype altered by iDC injection, but 
metabolic readouts of the sequelae of obesity were also modulated. 
We found that the glucose tolerance of iDC injected mice consuming a HFD was 
improved over control mice also on a HFD.  As opposed to the Ptges2 KO mice, where 
fat mass and glucose tolerance appeared unlinked, the iDC injected mice follow the 
more predictable pattern of decreased fat mass accompanying improved glucose 
tolerance.  Glucose tolerance was not improved all the way to lean values, but this does 
not rule out the possibility that altering the experimental design could improve the 
metabolic readouts even further and more closely approximate the lean values.  As was 
discussed in Chapter 3, we see a trend towards decreased liver TG in the iDC injected 
animals (Figure 15B), thus the possibility remains that incremental alterations in the 
experimental design could show a difference here as well.  Options would include 
maintaining the diet and injections for longer than six weeks, starting the injections prior 
to the start of the diet, or making the animals obese prior to intervention with iDC 
injections.  While allowing the mice to become obese and then starting iDC injections 
would be most analogous to any potential clinical application, this may also prove the 
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most difficult to induce differences, and thereby may not be informative of mechanism.  
In addition to introducing a new mechanism for macrophage-mediated alterations in 
metabolism (Chapter 2) and introducing a novel effector cell in the immune modulation 
of metabolism (Chapter 3), we also clarified an important scientific question regarding 
the involvement of NKT cells in the metabolic abnormalities of obesity (Chapter 4). 
Through the experiments performed in Chapter 4, we definitively showed that 
removal of NKT cells does not alter the development of the metabolic disturbances of 
obesity.  As explained previously, there was a controversy in the literature over whether 
NKT cells protected against, or exacerbated, insulin resistance and steatosis while 
consuming a HFD.  This controversy came to a head when Ohmura and colleagues 
published their results indicating that the β2-microglobulin (β2m) knock out mice were 
protected against diet-induced inflammation and insulin resistance [106]; however, as 
previously discussed, the β2m knock out mice also lack CD8+ T cells.  Our data, 
indicating specific removal of NKT cells does not alter weight gain, metabolic rate, 
inflammation or insulin resistance caused by HFD exposure, can now be put into 
context given the work of Nishimura et al., demonstrating that CD8+ T cells are involved 
in these processes [79].  Notably, removal of CD1d prevents the development of the 
invariant type NKT cells.  Different subsets of NKT cells may account for the results of 
other studies discussed in more detail in Chapter 4. 
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5.3 FUTURE DIRECTIONS 
In addition to the new experiments discussed above, which naturally followed 
from obtained results, this research has also led to some unanticipated new questions 
for future investigation.  In Chapter 2, I discussed how KC can lower hepatocyte lipid 
oxidation, however it is unknown whether other immune cells besides KC can also exert 
this effect.  We could easily test dendritic cells, T cells, B cells or other types of 
macrophages, e.g. BMDM, utilizing the co-culture system.  Furthermore, since TLR4 KO 
KC do not decrease hepatocyte oxidation, it would be interesting to measure PGE2 
production from TLR4 KO KC in response to palmitate, and if these cells do not produce 
PGE2, the next logical progression would be to determine what signaling cascade links 
TLR4 to PGE2.  Another question that arises in light of the responses seen to palmitate 
is whether other fatty acids have the same effect.  For example, do other saturated fatty 
acids longer, or shorter, than 16 carbons also induce PGE2 production from KC.  
Alternatively, do unsaturated fatty acids also have this effect?  Results discussed in 
Appendix A (Figure 23) would point towards PGE2 production in response to shorter, 
but potentially not longer, fatty acids.  Taking another step further, is PGE2 the only 
mediator of these effects?  The Luminex data presented in Figure 4 indicate that 
palmitate does not induce the production of TNFα, IFNγ or IL-10; however, this does not 
rule them out as also having effects on lipid metabolism.  By adding recombinant 
cytokines to mouse hepatocytes, we can screen many potential mediators of these 
effects.  We might predict that pro-inflammatory cytokines, such as TNFα, IL-6, IL-1, 
IFNγ and IL-12 would produce changes consistent with the development of steatosis, 
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while anti-inflammatory cytokines, such as IL-4 and IL-10, would oppose these changes.  
To obtain a more detailed analysis of how each of these cytokines may be involved, we 
can use a similar technique as described with the TLR4 KO KC co-culture experiment 
with cells obtained from, for example, TNFα or TNFα receptor knock out animals.   
We also do not know what changes occur within the hepatocyte to result in 
lowered oxidation and potentially increased TG accumulation.  Beyond the involvement 
of ACC, are these results a function of alterations in CPT1 activity or a lipid shuttling 
mechanism upstream from CPT1?  Since CPT1 is the rate-limiting step of β-oxidation, 
using octanoic acid, which bypasses this step, can help answer this question.  If PGE2 
does not decrease rates of octanoate oxidation, as it does in the case of palmitate, 
which is shuttled into the mitochondria by CPT1, we would conclude that PGE2 reduces 
palmitate oxidation at the level of CPT1.  We can also directly measure the CPT1 
activity in hepatocytes that have been treated with PGE2.  Furthermore, we could utilize 
transcription and translation inhibitors to determine whether these processes are 
required or phosphatase and kinase inhibitors to determine whether kinase cascades 
are involved.  Lastly, with regards to questions that could be addressed with our co-
culture system, I have shown that 5 hours of PGE2 treatment is sufficient to inhibit 
palmitate oxidation when palmitate is present overnight (Figure 5D); however, KC do 
not inhibit oxidation when palmitate is absent overnight (Figure 3A).  We interpret this 
result as a demonstration that palmitate is necessary to activate the KC overnight, and 
subsequently cause PGE2 production, but there is no evidence that the palmitate has no 
effect on the hepatocytes themselves.  Therefore, does a five-hour treatment of PGE2 
still cause a decrease in hepatocyte palmitate oxidation if palmitate is absent overnight? 
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A number of questions have also surfaced in response to our findings in Chapter 
3.  The major question that remains is that we still do not know the mechanism of 
protection afforded by iDC.  Are the injected iDC acting directly on parenchymal cells of 
the liver and WAT?  Are iDC recruiting other immune cells to exert effects on the 
tissues?  Are endogenous DC phagocytosing the iDC and presenting some unknown 
antigen to recruit other immune cells and affect tissue function?  Since DC have long 
been known to alter innate and adaptive immune responses via activation and 
recruitment of T and B cells [92], we have recently started to probe the involvement of T 
cells.  The DC-T cell interaction is classically mediated by the interaction of an MHC 
class II (MHCII)-antigen complex on the DC and the T cell receptor (TCR) on CD4+ T 
cells.  By injecting iDC generated from MHCII-null mice, we are testing the case where 
this interaction does not occur.  If injection of MHCII-null iDC does not afford the same 
protection as WT iDC, we can conclude that the injected DCs are interacting with 
endogenous T cells to exert the effects observed.  If, on the other hand, the MHCII-null 
iDC show the same effects as WT iDC, then either the endogenous DC are processing 
the injected DC or the injected DC are exerting their effects by a mechanism distinct 
from an MHCII-TCR interaction.  An alternative method would be to inject WT iDC into 
RAG knock out mice.  RAG knock outs do not produce T or B cells, thus if the injected 
cells were working through T or B cells, injection of iDC would not afford any protection 
in these animals.  Importantly, RAG knock out mice do become obese when placed on 
a HFD [136].  Additionally, we could utilize the flt3L KO mice to investigate the 
involvement of endogenous DC.  If endogenous DC are processing the injected DC, 
injection of iDC into flt3L KO mice, which do not have any endogenous DC, would not 
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respond to the injections with immune cell infiltration into WAT or a predominant TH2 
polarization of the tissues.  
A separate question related to immunotherapy is that we tested two types of DC 
and BMDM, but do any other cell types recapitulate the effects of iDC?  Other cell types 
that have been shown to affect insulin resistance, which could easily be tested, are 
CD4+ T cells [136], CD8+ T cells [79] and B cells [80].  As discussed previously, the goal 
of injecting these different cell types would be to attempt to induce not only a TH2 
immune response, as was seen with the iDC, but also a TH1 response, to determine if 
polarization is indeed the key factor in determining protection from diet-induced obesity, 
insulin resistance and steatosis.  We had hoped that the LPS-treated DC would induce 
a TH1 response, but the immunophenotype of liver, WAT and spleen all demonstrated a 
drop in the TNFα/IL-4 ratio in these animals similar to the animals receiving iDC 
injections (Supplemental Figure 6).  Given that animals receiving injections of LPS-DC 
were not afforded the same protection as those animals receiving iDC, we can again 
postulate that the determination of body composition and insulin sensitivity in response 
to immunotherapy is multi-factorial.  Finally, once all the cells are recruited and the 
cytokine milieu is determined, how do these factors actually alter the metabolic 
responses of the liver and adipose tissue?  One conjecture would be that a TH1 
polarized environment leads to the inhibitory serine phosphorylation of the insulin 
receptor in liver and WAT, thus dampening the insulin responsiveness of these tissues.  
Alternatively, a TH2 polarization could alter kinase cascades within the parenchymal 
cells to maintain lipid handling procedures in spite of increased substrate. 
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5.4 FINAL THOUGHTS 
In summary, as originally proposed in Figure 2, we believe that elevated 
circulating levels of FFA may be the initial factor that sets off a cascade of orchestrated 
changes leading to the sequelae of obesity.  These fatty acids activate signaling 
mechanisms within the parenchymal cells of the liver and adipose tissue, presumably 
via engaging TLR4, which promote the recruitment of macrophages and dendritic cells 
to these tissues.  Subsequently, FFA activate these recruited cells, which ultimately 
leads to alterations in the nutrient utilization procedures of hepatocytes and adipocytes.  
Based on our results from Chapter 3, DC are instrumental in directing the recruitment of 
many different cell types to the liver and adipose tissue.  In the setting of obesity, once 
present, the T cells and macrophages cooperate to create a TH1 polarized, pro-
inflammatory cytokine milieu, which promotes the steatosis, adiposity and insulin 
resistance, while certain subsets of DC may act to prevent this by driving a TH2 
response.  Concurrently, in the liver, FFA induce COX-1 & COX-2 within the KC to 
produce PGE2 with mPGES-1, which acts directly on the hepatocyte through the EP1 
receptor, to reduce β-oxidation rates and increase TG accumulation; changes which 
promote the development of steatosis and non-alcoholic fatty liver disease.  An 
important step in generating new treatments to combat the metabolic disturbances of 
obesity will be to more fully understand the potential influence of a TH2 polarized 
immunophenotype on nutrient metabolism and what actions can be taken to drive this 
response.  
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APPENDIX A - DEVELOPMENT OF MODEL SYSTEMS 
A.1 INTRODUCTION 
The use of animal model systems is a necessary alternative to the ethical conundrums 
posed by experimentation on humans.  Our model system of choice, house mice Mus 
musculus, are smaller, have a faster metabolism, and shorter breeding and life cycles 
than humans, in addition to providing the opportunity to work with knock outs which lack 
a specific gene of interest.  This allows us to ask very specific mechanistic questions 
and is an essential component of determining the inner workings of our cells’ 
physiology.  Even while using mice, however, yield of certain cell types is very low, 
limiting their potential for use in certain circumstances.  Kupffer cells (KC), the 
macrophages of the liver, are one such cell type.  Thus, one model system we sought to 
explore was the use of bone marrow-derived macrophages (BMDM) to serve as a 
surrogate for Kupffer cells.  Additionally, previous work from the lab has implicated 
dendritic cells (DC) in the development of the metabolic disturbances of obesity, thus 
we set out to investigate the use of bone marrow-derived dendritic cells (BMDC) as 
another surrogate. 
We also aimed to establish a model system to mimic the liver microenvironment 
in order to study the effects of immune cells on liver metabolism.  The liver has its own 
extensive resident immune system, consisting of B and T cells, NK cells, NKT cells, 
dendritic cells, and KC [71].  Our lab has previously set up a trans-well system of rat 
liver to investigate these interactions [91].  This allows us to maintain primary 
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hepatocytes in close proximity to, but preventing direct contact with, mononuclear cells; 
thus measuring changes due solely to the effects of soluble factors.  While metabolic 
studies of hepatocyte β-oxidation have been described in rats [91], the adaptation of this 
method for use with mouse hepatocytes would prove advantageous to ask directed 
mechanistic questions.  Until this point in time, however, a number of differences 
between rat and mouse hepatocytes have made this adaptation difficult.  Particularly, 
the trans-well inserts, used to co-culture the cells, themselves alter mouse hepatocyte 
metabolism in the absence of immune cells but not in rat hepatocytes.  Further, turnover 
of tritiated water decreases differences between experimental groups over longer tracer 
incubation times.   
In the following subsections, I describe the two main model systems I have been 
instrumental in developing during the course of my PhD training; namely a method of 
co-culturing mouse hepatocytes and immune cells to measure hepatocyte lipid 
metabolism, and the injection of bone marrow-derived immune cells into mice to acquire 
insight into the implications of exogenous administration of dendritic cells or 
macrophages.   
A.2 MATERIALS AND METHODS 
A.2.1 Hepatocyte isolation and cell culture  
Primary mouse hepatocytes were isolated using a non-recirculating in situ collagenase 
perfusion technique, modified as previously described [128].  A buffered salt solution 
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containing 0.95g/L EGTA was perfused, in situ, through the inferior vena cava, exiting 
the portal vein (retrograde to blood flow), to remove any blood contained in the liver.  
Subsequently, a 0.2mg/mL collagenase solution (type IV; Sigma C-5138, St. Louis, MO) 
was perfused to release hepatocytes and immune cells from the connective tissue.  
Livers were agitated to release cells, then hepatocytes were separated from other cells 
using a series of 40 x g spins and a 30% percoll gradient.  Resulting hepatocytes were 
counted, assessed for viability using Trypan Blue exclusion, resuspended at 0.5x106 
live hepatocytes/mL, then plated on type I collagen coated 6- or 24-well plates (Falcon 
35-3046 or 35-3047, respectively; collagen = Sigma C-8919) at a density of 1.2x106 
hepatocytes/6-well well or 2.5x105 hepatocytes/24-well well.  Non-attached cells were 
removed after 1 hour (45 min if in 24-well plates), by washing with RPMI 1640 
containing 10% heat inactivated FBS, 4.5g/L glucose, 1mM sodium pyruvate, 0.1mM 
nonessential amino acids, 2mM L-glutamine, 100U/mL penicillin, and 100ug/mL 
streptomycin [high glucose (HG) cRPMI].  Treatment media containing free fatty acid 
was prepared in HG cRPMI, and replaced the wash at the start of co-culture. 
A.2.2 Kupffer cell isolation and cell culture 
Liver mononuclear cells were isolated, modified as previously described [91].  The 
supernatants from the non-percoll hepatocyte centrifugations were centrifuged at 40 x g 
for 5 min, then the resultant supernatants were centrifuged at 375 x g.  The cell pellet 
containing non-parenchymal cells was resuspended in 2.7mL cRPMI (as above but with 
2.0g/L glucose) and mixed with 7.3mL 30% Histodenz (Sigma D-2158).  The resulting 
suspension was split into two aliquots of 5mL and layered under 5mL of cRPMI, and 
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centrifuged at 1425 x g for 20min at 22°C with no brakes.  Mononuclear cells remaining 
at the interphase between the two layers were collected and plated in cRPMI on 6-well 
plates (Falcon) or on trans-well inserts, as needed.  Kupffer cells (KC) were allowed to 
adhere to plates or inserts for 1 hour, then plating media was removed, along with non-
adherent mononuclear cells, and replaced with treatment media.  Additionally, control 
inserts plated with only cRPMI were also placed in the incubator for 1 hour, at the end of 
which, the cRPMI was replaced with treatment media. 
A.2.3 Hepatocyte and KC co-culture 
Liver mononuclear cells were plated in Transwell Permeable Supports (Corning, 
Corning, NY) at a density 1/3 that of the hepatocytes (thus, 4x105 in 6-well inserts or 
8.3x104 in 24-well inserts).  Once KC attach, 2mL HG cRPMI containing 0.4mM 
palmitate or BSA vehicle control was added to the insert, and 2mL treatment media was 
added directly to the hepatocytes (200uL to the insert and 800uL directly to hepatocytes 
in 24-well plates).  Hepatocytes and KC were co-cultured for 19 hours, then analyzed 
for palmitate oxidation, PGE2 production, or RT-PCR. 
A.2.4 Mouse primary hepatocyte fatty acid oxidation 
A.2.4.1  Original experimental design  
At the start of the co-culture, cells were incubated in the presence of 0.4mM palmitate 
and 2.5uCi/mL palmitic acid [9,10-3H(N)] (Perkin Elmer, Boston, MA).  Hepatocytes 
alone were compared to hepatocytes co-cultured with KC using a trans-well insert.  
 107 
After 19 hours in culture, palmitate oxidation was assessed by measuring the quantity of 
tritiated water released into the medium, as previously described [91,129].   
A.2.4.2  Updated experimental design 
Hepatocytes and KC were co-cultured in the presence of palmitate, octanoate, stearate, 
or oleate, but in the absence of the radioactive tracer, overnight.  Hepatocytes cultured 
in the presence of a trans-well insert with no cells added were compared to hepatocytes 
with KC attached to the insert.  After 14 hours in culture in the presence of 0.4mM fatty 
acid, 2.5uCi/mL tracer, either palmitic acid [9,10-3H(N)] (Perkin Elmer, Boston, MA), 
octanoic acid n-[8-3H], stearic acid [9,10-3H(N)] or oleic acid [9,10-3H(N)] (American 
Radiolabeled Chemicals, St. Louis, MO), was added to each well, with the 
corresponding fatty acid present, for 5 hours.  β-oxidation was assessed by measuring 
the quantity of tritiated water released into the medium.  Cell monolayers were washed 
twice with an excess volume of ice-cold PBS and collected in 1N NaOH for 
determination of protein content.   
A.2.5 Generation and culture of bone marrow-derived dendritic cells (BMDC) 
BMDC were generated from the culture of bone marrow progenitors, as previously 
described [101], originally adapted from the work of Inaba, et al. [158] and Lu, et al. 
[159].  Briefly, bone marrows, isolated from femur and tibia, were depleted of RBCs 
using Red Blood Cell Lysing Buffer (Sigma R7757), and of T cells, B cells and MHC 
class-II expressing cells using monoclonal antibody and complement treatment.  The 
remaining cells were cultured in serum free AIM-V medium (Gibco 12055) with 1mM 
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sodium pyruvate, 0.1mM nonessential amino acids, 2mM L-glutamine, 100U/mL 
penicillin, 100ug/mL streptomycin and 0.00035% β-mercaptoethanol (Sigma M7522) 
containing 5ng/mL GM-CSF for 5 days.  On day two, 50% of the medium was replaced 
with fresh AIM-V with GM-CSF.  On day 5, half of the cultured cells were treated with 
1ug/mL LPS (Sigma L-3012) for two hours to generate activated BMDC (LPS-DC).  
Untreated, immature BMDC (iDC) and LPS-DC were purified using CD11c magnetic 
beads (Miltenyi Biotec, Auburn, CA), according to the manufacturer’s instructions. 
A.2.6 Generation and culture of bone marrow-derived macrophages (BMDM) 
BMDM were generated from the culture of bone marrow progenitors, as previously 
described [137], originally adapted from the work of Davis and Gordon [160].  Briefly, 
bone marrows, isolated from femur and tibia, were depleted of RBCs using Red Blood 
Cell Lysing Buffer (Sigma R7757).  Cells were plated on 150x15mm petri dishes (VWR 
25384-326) at a density of 1x107/dish (day 0) and cultured in DMEM supplemented with 
20% heat-inactivated FBS, 1mM sodium pyruvate, 2mM L-glutamine, 100U/mL 
penicillin, 100ug/mL streptomycin and 30% L-cell supernatant, which is generated by 
incubating L-cell fibroblasts (CCL-1 from ATCC, gift of Dr. R. Salter) in DMEM 
supplemented with 10% heat-inactivated FBS, 1mM sodium pyruvate, 0.1mM 
nonessential amino acids, 2mM L-glutamine, 100U/mL penicillin, and 100ug/mL 
streptomycin, until confluent.  Supernatants were passed through a 0.2um filter and 
stored at -80°C until preparing media.  Differentiation media was changed 3-4 days after 
initial plating, then subcultured every 4th day thereafter.  BMDM were used for 
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experiments on day 7 for injections after a negative selection for CD11c using MACS 
beads (Miltenyi Biotec, Auburn, CA), according to the manufacturer’s instructions.   
A.2.7 Mouse TNFα ELISA 
Cells were plated at a density of 4x106 per well in 6-well plates.  Cells were cultured for 
19 hours in the presence of 0.4mM palmitate or 1.15% BSA (vector control, Sigma 
A7030).  The next morning, cell culture supernatants were collected and stored at -20°C 
until Mouse TNF-α Quantikine Immunoassay (R&D Systems, MTA00, Minneapolis, MN) 
was performed, according to the manufacturer’s instructions. 
A.2.8 Quantification of cytokine production 
Cell culture supernatants from various cell treatments were collected after 19 hours of 
culture, and assayed for the presence of 23 cytokines/chemokines (IL-1α, 1β, 2, 4, 5, 6, 
10, 12(p40), 12(p70), 13, and 17, TNFα, IFN-γ, IP-10, CXCL1, MCP-1, M-CSF, MIG, 
MIP-1α, MIP-1β, MIP-2, RANTES, and GM-CSF) using a Milliplex Luminex Kit 
(Millipore), according to the manufacturer’s instructions.   
A.2.9 PGE2 EIA 
PGE2 released into the cell culture medium by co-culture or monoculture was measured 
using a commercial kit (by EIA; Cayman Chemical, Ann Arbor, MI) according to the 
protocol provided by the manufacturer.   
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A.3 MOUSE CO-CULTURE SYSTEM 
A.3.1 Effects of Kupffer cells and trans-well inserts on hepatocyte palmitate 
oxidation 
Previous studies have reported decreases in rat hepatocyte palmitate oxidation when 
co-cultured with rat KC in the presence of LPS [91].  A direct adaptation of that system, 
using mouse hepatocytes and KC generated a large artifact (Figure 22A).  We 
discovered that the trans-well insert itself, with no immune cells added, decreased the 
palmitate oxidation in mouse hepatocytes (Figure 22A).  Even with the effect of the 
insert, there was a reproducible, but small, difference between the Hepatocytes+Insert 
and Hepatocytes+KC groups.  We therefore set out to alter the experimental conditions 
to increase this difference while maintaining the effect of KC. 
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Figure 22 - Palmitate-activated KC and trans-well inserts decrease hepatocyte palmitate 
oxidation. 
 
(A) Primary hepatocytes (Heps) from C57Bl/6 mice were mono-cultured overnight in the presence 
of 0.4mM palmitate (column 1), co-cultured with KC that were attached to a trans-well insert 
(column 3), or cultured in the presence of a trans-well insert with no cells present (column 2), as 
described in the Original experimental design Mouse Primary Hepatocyte Fatty Acid Oxidation 
method (A.2.4.1).  (B) Alternatively, primary hepatocytes from C57Bl/6 mice were mono-cultured 
overnight in the presence of 0.4mM palmitate (column 1), co-cultured with KC that were attached 
to a trans-well insert (column 3), or cultured in the presence of a trans-well insert with no cells 
present (column 2), as described in the Updated experimental design Mouse Primary Hepatocyte 
Fatty Acid Oxidation method (A.2.4.2).  Results are presented as the means±SE for four 
experiments performed in triplicate.  *p<0.05, **p<0.005, ***p<0.0005. 
 
A.3.2 Determination of optimal tracer exposure time for mouse hepatocyte 
palmitate oxidation 
The radioactive palmitate tracer allows for the total β-oxidation to be measured.  Based 
on the length of time the tracer is present, a certain amount of tracer will be oxidized, 
transferring the tritium atoms to water, which is captured by evaporative exchange.  We 
tested a number of different exposure times, and found that if we co-cultured the cells 
for 14 hours and then added the tracer to the culture medium for the final 5 hours of the 
experiment, we were able to minimize the effect of the trans-well insert, and maximize 
the effect of the KC (Figure 22B).  Oxidation levels when the tracer was present for only 
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the final 3 hours were still affected by the insert, and statistical differences were not 
achieved between the +Insert and +KC conditions.  Similar results were obtained when 
testing a 4 hour co-culture with tracer present for the entire time.  Additionally, an 8 hour 
co-culture with tracer present for the entire duration of the culture, showed no difference 
between the Hepatocytes+Insert and Hepatocytes+KC groups (data not shown).   
A.3.3 Effects of KC on fatty acid oxidation 
Given our evidence that palmitate, in and of itself, is capable of acting on the Kupffer 
cells to alter the level of β-oxidation (see also Chapter 2), we wanted to test the ability of 
other fatty acids to produce similar effects.  Using the updated experimental design and 
utilizing palmitate (C16:0, Figure 23A), octanoate (C8:0, Figure 23B), stearate (C18:0, 
Figure 23C), or oleate (C18:1 cis-9, Figure 23D) as fatty acid substrates, and the 
radioactive tracer with the corresponding tritiated fatty acid, we measured β-oxidation 
levels in the presence or absence of KC.  We saw the same effect on β-oxidation when 
we used octanoate as our substrate as with palmitate.  These data were particularly 
interesting, because octanoate, as a short to medium chain fatty acid, is not shuttled 
through CPT-1 into the mitochondria.  This speaks to how lipids are handled in the 
presence of KC regardless of the mode of delivery.  We also did not find a decrease 
with the long chain saturated fatty acid stearate, nor the mono-unsaturated fatty acid 
oleate.  Additionally, the effect of palmitate on KC is dependent on TLR4 (see Chapter 
2).  Taken together, these data would indicate that fatty acids above a certain length 
may not be able to trigger action through TLR4, thus not inducing the detrimental effects 
on lipid oxidation.   
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Figure 23 - KC decrease hepatocyte oxidation of palmitate and octanoate, but not oleate or 
stearate.   
 
Kupffer cells and hepatocytes were co-cultured overnight in the presence of 0.4mM fatty acid 
utilizing the Updated experimental design as described in Methods (A.2.4.2).  Hepatocytes 
cultured with an empty insert (Heps+In) were compared to hepatocytes co-cultured with KC 
(Heps+KC).  Results are presented as the means±SE for a minimum of five experiments 
performed in triplicate.  *p<0.05. 
A.4 INJECTION OF BONE MARROW-DERIVED IMMUNE CELLS 
A.4.1 Differences between various immune cell lines 
In previous chapters, we described the use of various immune cell lines and immune 
cell primary cultures.  KC, BMDC, and BMDM are used most extensively to describe the 
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effects of immune cells on lipid metabolism and the metabolic disturbances of obesity.  
We were particularly interested in utilizing the BMDM as a model for KC, since the yield 
of KC from a mouse liver is extremely small.  BMDM are much more abundant and 
easier to manipulate, therefore, the applications and potential for new experiments 
would greatly expand.  As explored more fully in Chapter 2, we have attributed a role for 
the prostanoid PGE2 in the effects of KC on hepatocyte lipid metabolism.  We, 
therefore, started by comparing the ability of KC and BMDM to generate PGE2 in 
response to palmitate (Figure 24A).  As the data shows, KC generate roughly four times 
more PGE2 in the presence of palmitate compared to vehicle (BSA), while BMDM show 
no difference.  Notably, the basal levels of PGE2 production were similar between the 
two cell types (KC 80±19 pg/mL; BMDM 101±46 pg/mL; average±SEM).  The pro-
inflammatory cytokine TNFα has been implicated in the metabolic disturbances of 
obesity [8,9,91].  We, therefore, were also interested in comparing the TNFα production 
in these cells in response to palmitate.  We found that KC trend towards dropping TNFα 
production while levels were undetectable in BMDM culture supernatants in the 
presence or absence of palmitate (Figure 24B).  Additionally, as a further control, RAW 
cells, an immortalized mouse macrophage cell line, exhibited an increase in TNFα 
production in the presence of palmitate (Figure 24B).  Thus, the findings showed that 
BMDM and KC respond differently to stimulation by palmitate, suggesting BMDM are 
not the optimal surrogate cell type for KC in this model. 
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Figure 24 - Macrophage comparison via prostaglandin E2 (PGE2) synthesis and TNFα  
production in response to palmitate. 
 
(A) KC and bone marrow-derived macrophages were cultured overnight in the presence or 
absence of 0.4mM palmitate, after which cell culture media was collected and analyzed for PGE2 
concentration, as described in Methods.  (B) KC, BMDM and RAW cells were cultured overnight 
in the presence or absence of 0.4mM palmitate, after which cell culture media was collected and 
analyzed for TNFa concentration, as described in Methods.  Results are presented as the 
means±SE for a minimum of 3 experiments performed in duplicate.  *p<0.05 compared to BSA. 
 
A.4.2 Immune cells as therapy 
In Chapter 3, we used an exogenous cell transfer technique to alter the development of 
obesity, insulin resistance and steatosis in mice when they are placed on a high fat diet 
for seven weeks.  Additionally, we have used a separate, shorter (one week) 
experimental design to address changes specifically in the immunophenotype of these 
animals.  Dendritic cells only survive in vivo for approximately 3 days [101], therefore we 
decided to give injections of DC every week for the duration of the experiments (thus six 
injections during the course of the seven week experiments, starting with the first 
injection at the time of starting the HFD, and a single injection for the shorter-term 
experiments).  There was always at least one week between the time of the last 
injection and sacrifice of the animals.  In this manner, we could minimize any influence 
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the physically injected cells may have had on the final analysis.  Most of the data from 
this project was presented in Chapter 3; however, as a first pass, to characterize the 
cells, we performed Luminex on overnight cultures of the injected cells (Figure 25).  Not 
surprisingly, the LPS-stimulated BMDC showed higher production of the pro-
inflammatory cytokines TNFα and IL-6 (Figures 25A&B).  Additionally, the BMDMs 
produced significantly more MCP-1 and significantly less RANTES than either immature 
or LPS-DC (Figure 25 C&D). 
 
Figure 25 - Cytokine production of bone marrow-derived immune cells.   
 
BMDM, iDC and LPS-DC were generated, as described in Methods.  After injection into mice, 
remaining cells were kept in culture overnight.  Supernatants were collected and analyzed by 
Luminex, as described in Methods.  Data is shown for TNFa (A), IL-6 (B), MCP-1 (C), and 
RANTES (D).  Results are presented as the concentration of each cytokine produced by the 
injected cells from the individual week indicated.  *p<0.05, ***p<0.0005. 
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APPENDIX B - SUPPLEMENTAL FIGURES 
 
Supplemental Figure 1 - Caloric intake of DC and macrophage injected mice. 
Wild-type C57Bl/6 mice were placed on a SCD or HFD for 6 weeks and injected once per week 
with either PBS, 1x106 immature BMDC (iDC), 1x106 LPS treated BMDC (LPS-DC) or 1x106 bone 
marrow-derived macrophages (BMDM).  Caloric intake was assessed, as described in Methods.  
Results are presented as the means±SE for an n of 4 (A) or 2 (B) cages in each group. 
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Supplemental Figure 2 - Liver FACS analysis of iDC injected mice. 
Liver was collected from SC, HFD, PBS injected, and iDC injected mice, immune cells were 
isolated and analyzed by FACS, as described in Methods.  (A) Gating scheme for T cell stain 
(top) and DC/Macrophage stain (bottom).  (B) Total numbers of CD3+CD4+, CD3+CD4+FoxP3+, 
CD11c+, and CD11b+CD11c- cells in the liver were quantified. Results are presented as the 
means±SE for a minimum of seven animals in each group.  *p<0.05. 
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Supplemental Figure 3 - Spleen FACS analysis of iDC injected mice. 
Spleen was collected from SC, HFD, PBS injected, and iDC injected mice, immune cells were 
isolated and analyzed by FACS, as described in Methods.  (A) Gating scheme for T cell stain 
(top) and DC/Macrophage stain (bottom).  (B) Total numbers of CD3+CD4+, CD3+CD4+FoxP3+, 
CD11c+, and CD11b+CD11c- cells in the spleen were quantified. Results are presented as the 
means±SE for a minimum of seven animals in each group. 
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Supplemental Figure 4 - WAT Luminex analysis of iDC injected mice. 
Complete Luminex analysis of WAT immune cells (continuation from Figure 13C).  Immune cells, 
isolated from WAT, were kept in culture overnight in the presence of 10ng/mL PMA and 
500ng/mL ionomycin. Subsequently, supernatants underwent Luminex analysis, as described in 
Methods.  Results are presented as the means±SE for five-six animals in each group.  *p<0.05. 
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Supplemental Figure 5 - Liver Luminex analysis of iDC injected mice. 
Immune cells, isolated from liver, were kept in culture overnight in the presence of 10ng/mL PMA 
and 500ng/mL ionomycin. Subsequently, supernatants underwent Luminex analysis, as 
described in Methods.  Results are presented as the means±SE for six animals in each group.  
*p<0.05. 
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Supplemental Figure 6 - Luminex analysis of DC and macrophage injected mice. 
Immune cells, isolated from WAT, liver and spleen, were kept in culture overnight. Subsequently, 
supernatants underwent Luminex analysis, as described in Methods.  Results are presented as 
the means±SE for five animals in each group.  *p<0.05, **p<0.005. 
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